Teleflex (TFX) 10-K23 Feb 232022 FY Annual reportFinancial data

Company Profile

Cover page

Cover page - USD ($)	12 Months Ended
Cover page - USD ($)	Dec. 31, 2022	Feb. 21, 2023	Jun. 26, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-5353
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-1147939
Entity Address, Address Line One	550 East Swedesford Road, Suite 400
Entity Address, City or Town	Wayne
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	610
Local Phone Number	225-6800
Title of 12(b) Security	Common Stock, par value $1.00 per share
Trading Symbol	TFX
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,944,155
Entity Public Float			$ 6,990,562,114
Documents Incorporated by Reference	Certain provisions of the registrant’s definitive proxy statement in connection with its 2023 Annual Meeting of Stockholders, to be filed within 120 days of the close of the registrant’s fiscal year, are incorporated by reference in Part III hereof.(1) For purposes of this computation only, the registrant has defined “affiliate” as including executive officers and directors of the registrant and owners of more than five percent of the common stock of the registrant, without conceding that all such persons are “affiliates” for purposes of the federal securities laws.
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0000096943

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Philadelphia, Pennsylvania

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net revenues	$ 2,791,041	$ 2,809,563	$ 2,537,156
Cost of goods sold	1,259,954	1,259,961	1,212,282
Gross profit	1,531,087	1,549,602	1,324,874
Selling, general and administrative expenses	863,748	860,085	743,568
Research and development expenses	153,819	130,841	119,747
Restructuring and impairment charges	20,299	21,738	38,491
Gain on sale of assets and business	(6,504)	(91,157)	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	499,725	628,095	423,068
Interest expense	54,264	56,969	66,494
Interest income	(912)	(1,328)	(1,158)
Loss on extinguishment of debt	454	12,986	0
Income from continuing operations before taxes	445,919	559,468	357,732
Taxes on income from continuing operations	83,003	74,349	21,931
Income from continuing operations	362,916	485,119	335,801
Operating income (loss) from discontinued operations	260	331	(621)
Taxes (benefit) on operating loss from discontinued operations	37	76	(144)
Income (loss) from discontinued operations	223	255	(477)
Net income	$ 363,139	$ 485,374	$ 335,324
Basic:
Income from continuing operations (in dollars per share)	$ 7.74	$ 10.37	$ 7.22
Income (loss) from discontinued operations (in dollars per share)	0	0.01	(0.01)
Net income (in dollars per share)	7.74	10.38	7.21
Diluted:
Income from continuing operations (in dollars per share)	7.67	10.23	7.10
Income (loss) from discontinued operations (in dollars per share)	0.01	0	(0.01)
Net income (loss), diluted (in dollar per share)	$ 7.68	$ 10.23	$ 7.09
Weighted average shares outstanding:
Basic (in shares)	46,898	46,774	46,488
Diluted (in shares)	47,309	47,427	47,287

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 363,139	$ 485,374	$ 335,324
Foreign currency:
Foreign currency translation adjustments, net of tax of $(6,634), $(5,563) and $6,442, respectively	(62,904)	(63,191)	59,758
Foreign currency translation, net of tax	(62,904)	(63,191)	59,758
Pension and other postretirement benefits plans:
Prior service cost recognized in net periodic cost, net of tax of $232, $232 and $(7), respectively	(785)	(780)	26
Unamortized (loss) gain arising during the period, net of tax of $850, $(1,671) and $6,101, respectively	(3,649)	5,582	(19,966)
Plan amendments, curtailments, and settlements, net of tax of $0, $0 and $(1,067), respectively	0	0	3,544
Net loss recognized in net periodic cost, net of tax of $(1,778), $(1,988) and $(1,694), respectively	5,882	6,555	5,559
Foreign currency translation, net of tax of $(366), $(238) and $243, respectively	1,043	610	(610)
Pension and other postretirement benefits plans adjustment, net of tax	2,491	11,967	(11,447)
Derivatives qualifying as hedges:
Unrealized gain (loss) on derivatives arising during the period, net of tax $(551), $(27) and $234, respectively	7,179	351	(3,331)
Reclassification adjustment on derivatives included in net income, net of tax of $203, $62 and $(240), respectively	(3,329)	1,212	2,114
Derivatives qualifying as hedges, net of tax	3,850	1,563	(1,217)
Other comprehensive (loss) income, net of tax	(56,563)	(49,661)	47,094
Comprehensive income	$ 306,576	$ 435,713	$ 382,418

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Foreign currency translation, continuing operations, adjustments, tax	$ (6,634)	$ (5,563)	$ 6,442
Prior service cost recognized in net periodic cost, tax	232	232	(7)
Unamortized (loss) gain arising during the period, tax	850	(1,671)	6,101
Plan amendments, curtailments, and settlements, tax	0	0	(1,067)
Net loss recognized in net periodic cost, tax	(1,778)	(1,988)	(1,694)
Foreign currency translation, tax	(366)	(238)	243
Unrealized gain (loss) on derivatives arising during the period, tax	(551)	(27)	234
Reclassification adjustment on derivatives included in net income, tax	$ 203	$ 62	$ (240)

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 292,034	$ 445,084
Accounts receivable, net	408,834	383,569
Inventories	578,507	477,643
Prepaid expenses and other current assets	125,084	117,277
Prepaid taxes	6,524	5,545
Total current assets	1,410,983	1,429,118
Property, plant and equipment, net	447,205	443,758
Operating lease assets	131,211	129,653
Goodwill	2,536,730	2,504,202
Intangibles assets, net	2,306,165	2,289,067
Deferred tax assets	6,402	6,820
Other assets	89,367	69,104
Total assets	6,928,063	6,871,722
Current liabilities
Current borrowings	87,500	110,000
Accounts payable	126,807	118,236
Accrued expenses	140,644	163,441
Payroll and benefit-related liabilities	133,092	143,657
Accrued interest	5,332	5,209
Income taxes payable	24,736	83,943
Other current liabilities	63,381	55,633
Total current liabilities	581,492	680,119
Long-term borrowings	1,624,023	1,740,102
Deferred tax liabilities	388,886	370,124
Pension and postretirement benefit liabilities	31,394	45,185
Noncurrent liability for uncertain tax positions	5,805	8,646
Noncurrent operating lease liabilities	120,437	116,033
Other liabilities	154,058	156,765
Total liabilities	2,906,095	3,116,974
Commitments and contingencies
Shareholders’ equity
Common shares, $1 par value Issued: 2022 — 47,957 shares; 2021 — 47,929 shares	47,957	47,929
Additional paid-in capital	715,118	693,090
Retained earnings	3,817,304	3,517,954
Accumulated other comprehensive loss	(403,522)	(346,959)
Shareholders equity before treasury stock, total	4,176,857	3,912,014
Less: Treasury stock, at cost	154,889	157,266
Total shareholders' equity	4,021,968	3,754,748
Total liabilities and shareholders' equity	$ 6,928,063	$ 6,871,722

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common shares, par value (in dollars per share)	$ 1	$ 1
Common shares, shares issued (in shares)	47,957	47,929

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities of continuing operations:
Net income	$ 363,139	$ 485,374	$ 335,324
Adjustments to reconcile net income to net cash provided by operating activities:
(Income) loss from discontinued operations	(223)	(255)	477
Depreciation expense	66,502	71,758	68,567
Intangible asset amortization expense	164,088	165,604	158,685
Deferred financing costs and debt discount amortization expense	4,053	4,493	4,430
Loss on extinguishment of debt	454	12,986	0
Fair value step up of acquired inventory sold	0	3,993	1,707
Changes in contingent consideration	2,350	8,475	(38,164)
Assets impairment charges	1,497	6,739	21,388
Stock-based compensation	27,224	22,937	20,739
Gain on sale of assets and business	(6,504)	(91,157)	0
Deferred income taxes, net	(13,008)	(110,239)	(32,675)
Payments for contingent consideration	(3,016)	(230)	(79,801)
Interest benefit on swaps designated as net investment hedges	(20,880)	(19,296)	(19,178)
Other	(2,906)	(36,388)	(26,636)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(38,459)	(600)	44,748
Inventories	(110,686)	(11,138)	(5,497)
Prepaid expenses and other current assets	13,420	(28,410)	(4,323)
Accounts payable, accrued expenses and other liabilities	(24,786)	94,020	646
Income taxes	(79,453)	73,473	(13,294)
Net cash provided by operating activities from continuing operations	342,806	652,139	437,143
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(79,190)	(71,618)	(90,694)
Payments for businesses and intangibles acquired, net of cash acquired	(198,429)	(4,590)	(767,830)
Proceeds from sales of business and assets	12,434	224,909	1,400
Net interest proceeds on swaps designated as net investment hedges	20,775	19,154	19,341
Proceeds from sales of investments	7,300	7,300	0
Purchase of investments	(22,300)	(18,418)	0
Net cash (used in) provided by investing activities from continuing operations	(259,410)	156,737	(837,783)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	744,250	400,000	1,513,807
Reduction in borrowings	(884,500)	(1,034,500)	(938,807)
Debt extinguishment, issuance and amendment fees	(5,200)	(9,774)	(8,440)
Net proceeds from share based compensation plans and the related tax impacts	(4,308)
Net proceeds from share based compensation plans and the related tax impacts		12,451	18,994
Payments for contingent consideration	(3,959)	(31,448)	(67,170)
Dividends paid	(63,789)	(63,648)	(63,221)
Proceeds from sale of treasury stock	0	11,097	0
Net cash (used in) provided by financing activities from continuing operations	(217,506)	(715,822)	455,163
Cash flows from discontinued operations:
Net cash used in operating activities	(665)	(720)	(737)
Net cash provided by investing activities	1,469	0	0
Net cash provided by (used in) discontinued operations	804	(720)	(737)
Effect of exchange rate changes on cash and cash equivalents	(19,744)	(23,130)	21,011
Net (decrease) increase in cash and cash equivalents	(153,050)	69,204	74,797
Cash and cash equivalents at the beginning of the year	445,084	375,880	301,083
Cash and cash equivalents at the end of the year	$ 292,034	$ 445,084	$ 375,880

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid in Capital	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss (income)	Treasury Stock, Common
Common stock, shares issued, beginning balance (in shares) at Dec. 31, 2019			47,536
Common stock, shares issued, ending balance (in shares) at Dec. 31, 2020			47,812
Treasury shares, beginning balance (in shares) at Dec. 31, 2019								1,182
Beginning Balance at Dec. 31, 2019	$ 2,979,320	$ (791)	$ 47,536	$ 616,980	$ 2,824,916	$ (791)	$ (344,392)	$ (165,720)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	335,324				335,324
Cash dividends	(63,221)				(63,221)
Other comprehensive income (loss)	47,094						47,094
Shares issued under compensation plans (in shares)			276					(44)
Shares issued under compensation plans	37,732		$ 276	35,223				$ 2,233
Deferred compensation (in shares)								(6)
Deferred compensation	999			102				$ 897
Treasury shares, ending balance (in shares) at Dec. 31, 2020								1,132
Ending Balance at Dec. 31, 2020	$ 3,336,457		$ 47,812	652,305	3,096,228		(297,298)	$ (162,590)
Common stock, shares issued, ending balance (in shares) at Dec. 31, 2021	47,929		47,929
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 485,374				485,374
Cash dividends	(63,648)				(63,648)
Other comprehensive income (loss)	(49,661)						(49,661)
Shares issued under compensation plans (in shares)			117					(31)
Shares issued under compensation plans	34,453		$ 117	33,989				$ 347
Treasury stock reissued	11,097			6,349				$ 4,748
Treasury stock reissued (in shares)								(28)
Deferred compensation (in shares)								(4)
Deferred compensation	676			447				$ 229
Treasury shares, ending balance (in shares) at Dec. 31, 2021								1,069
Ending Balance at Dec. 31, 2021	$ 3,754,748		$ 47,929	693,090	3,517,954		(346,959)	$ (157,266)
Common stock, shares issued, ending balance (in shares) at Dec. 31, 2022	47,957		47,957
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 363,139				363,139
Cash dividends	(63,789)				(63,789)
Other comprehensive income (loss)	(56,563)						(56,563)
Shares issued under compensation plans (in shares)			28					(32)
Shares issued under compensation plans	23,502		$ 28	21,930				$ 1,544
Deferred compensation (in shares)								(5)
Deferred compensation	931			98				$ 833
Treasury shares, ending balance (in shares) at Dec. 31, 2022								1,032
Ending Balance at Dec. 31, 2022	$ 4,021,968		$ 47,957	$ 715,118	$ 3,817,304		$ (403,522)	$ (154,889)

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Dividends, per common share (in dollars per share)	$ 1.36	$ 1.36	$ 1.36

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
Summary of significant accounting policies	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Consolidation: The consolidated financial statements include the accounts of Teleflex Incorporated and its subsidiaries (referred to herein as “we,” “us,” “our” and “Teleflex"). Intercompany transactions are eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and reflect management’s estimates and assumptions that affect the recorded amounts. Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Cash and cash equivalents: All highly liquid debt instruments with an original maturity of three months or less are classified as cash equivalents. The carrying value of cash equivalents approximates the current market value. Accounts receivable: Accounts receivable represent amounts due from customers related to the sale of products and provision of services. Our allowance for credit losses is maintained for trade accounts receivable based on the expected collectability of accounts receivable and losses expected to be incurred over the life of our receivables. Considerations to determine credit losses include our historical collection experience, the length of time an account is outstanding, the financial position of the customer, information provided by credit rating services, as well as the consideration of events or circumstances indicating historic collection rates may not be indicative of future collectability. The allowance for credit losses as of December 31, 2022 and December 31, 2021 was $8.6 million and $10.8 million, respectively. The current portion of the allowance for credit losses, which was $4.9 million and $6.0 million as of December 31, 2022 and December 31, 2021, respectively, was recognized as a reduction of accounts receivable, net. Inventories: Inventories are valued at the lower of cost or net realizable value. The cost of our inventories is determined using the average cost method. Elements of cost in inventory include raw materials, direct labor, and manufacturing overhead. In estimating net realizable value, we evaluate inventory for excess and obsolete quantities based on estimated usage and sales, among other factors. Property, plant and equipment: Property, plant and equipment are stated at cost, net of accumulated depreciation. Costs incurred to develop internal-use computer software during the application development stage generally are capitalized. Costs of enhancements to internal-use computer software are capitalized, provided that these enhancements result in additional functionality. Other additions and those improvements which increase the capacity or lengthen the useful lives of the assets are also capitalized. Composite useful lives for categories of property, plant and equipment, which are depreciated on a straight-line basis, are as follows: buildings — 30 years; machinery and equipment — 3 to 15 years; computer equipment and software — 3 to 10 years. Leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the remaining lease term. Repairs and maintenance costs are expensed as incurred. Goodwill and other intangible assets: Goodwill and other indefinite-lived intangible assets are not amortized but are tested for impairment annually during the fourth quarter or more frequently if events or changes in circumstances indicate that an impairment may exist. Impairment losses, if any, are included in income from operations. The goodwill impairment test is applied to each of our reporting units. For purposes of this assessment, a reporting unit is an operating segment, or a business one level below an operating segment (also known as a component) if discrete financial information is prepared for that business and regularly reviewed by segment management. However, separate components are aggregated as a single reporting unit if they have similar economic characteristics. In performing the goodwill impairment test, we may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors may include, but are not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for our products and services, regulatory and political developments, and entity specific factors such as strategies and financial performance. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying value, we proceed to a quantitative impairment test, described below. Alternatively, we may elect to bypass the qualitative assessment and perform the quantitative impairment test. Under a quantitative impairment test, we compare the fair value of a reporting unit to its carrying value. If the reporting unit fair value exceeds the carrying value, there is no impairment. If the reporting unit carrying value exceeds the fair value, we recognize an impairment loss based on the amount the carrying value of the reporting unit exceeds its fair value. We did not record a goodwill impairment charge for the year ended December 31, 2022. Our intangible assets consist of customer relationships, intellectual property, distribution rights, in-process research and development ("IPR&D"), trade names and non-competition agreements. We define IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and is required be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or upon abandonment. Upon completion of the development project (generally when regulatory approval to market the product that utilizes the technology is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off. We test our indefinite-lived intangible assets for impairment annually, or more frequently if events or changes in circumstances indicate that an impairment may have occurred. Similar to the goodwill impairment test process, we may elect to perform a qualitative assessment. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of the indefinite-lived intangible asset is greater than its carrying amount, the asset is not impaired. If we conclude it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, we then proceed to a quantitative impairment test, which consists of a comparison of the fair value of the intangible asset to its carrying amount. Intangible assets that do not have indefinite lives, consisting of intellectual property, customer relationships, distribution rights, certain trade names and non-competition agreements, are amortized over their estimated useful lives, which are as follows: intellectual property, 5 to 20 years; customer relationships, 8 to 27 years; distribution rights, 10 years; trade names, 10 to 30 years; non-compete agreement, 6 years. The weighted average remaining amortization period with respect to our intangible assets is approximately 15 years. We periodically evaluate the reasonableness of the useful lives of these assets. Long-lived assets: We assess the remaining useful life and recoverability of long-lived assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The assessment is based on various analyses, including undiscounted cash flow and profitability projections that incorporate, as applicable, the impact of the asset on the existing business. Therefore, the evaluation involves significant management judgment. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset. Foreign currency translation: Assets and liabilities of subsidiaries with non-United States dollar denominated functional currencies are translated into United States dollars at the rates of exchange at the balance sheet date; income and expenses are translated at the average rates of exchange prevailing during the year. The translation adjustments are reported as a component of accumulated other comprehensive loss. Derivative financial instruments: We use derivative financial instruments primarily for purposes of hedging exposures to fluctuations in foreign currency exchange rates. All instruments are entered into for other than trading purposes. All derivatives are recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recorded in the consolidated statement of comprehensive income as other comprehensive income (loss), if the instrument is designated as part of a hedge transaction. Gains or losses on derivative instruments reported in other comprehensive income (loss) are reclassified to the consolidated statement of income in the period in which earnings are affected by the underlying hedged item. Gains or losses on derivative instruments representing hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, if any, are recognized in the consolidated statement of income for the period in which such gains and losses occur. If the hedging relationship ceases to be highly effective or it becomes probable that an expected transaction will no longer occur, gains or losses on the derivative instrument are recorded in the consolidated statement of income for the period in which either such event occurs. For non-designated derivatives, gains and losses are reported as selling, general and administrative expenses in the consolidated statement of income. Cash flows from derivatives are recognized in the consolidated statements of cash flows in a manner consistent with the recognition of the underlying transactions. Share-based compensation: We estimate the fair value of share-based awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest, which is derived, in part, following consideration of estimated forfeitures, is recognized as expense over the requisite service periods. Share-based compensation expense related to stock options is measured using a Black-Scholes option pricing model that takes into account subjective and complex assumptions with respect to the expected life of the options, volatility, risk-free interest rate and expected dividend yield. The expected life of options granted is derived from the vesting period of the award, as well as historical exercise behavior, and represents the period of time that options granted are expected to be outstanding. Expected volatility is based on a blend of historical volatility and implied volatility derived from publicly traded options to purchase our common stock, which we believe is more reflective of market conditions and a better indicator of expected volatility than would be the case if we only used historical volatility. The risk-free interest rate is the implied yield currently available on United States (or "U.S.") Treasury zero-coupon issues with a remaining term equal to the expected life of the option. Forfeitures are estimated at the time of grant based on management’s expectations regarding the extent to which awards ultimately will vest and are adjusted for actual forfeitures when they occur. Income taxes: The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, and to reflect operating loss and tax credit carryforwards. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Provision has been made for income taxes on unremitted earnings of subsidiaries and affiliates, except to the extent that such earnings are deemed to be permanently reinvested. Significant judgment is required in determining income tax provisions and in evaluating tax positions. We establish additional provisions for income taxes when, despite the belief that tax positions are supportable, there remain certain positions that do not meet the minimum probability threshold, which is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority. In the normal course of business, we are examined by various federal, state and non-U.S. tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of our provision for income taxes. Interest accrued with respect to unrecognized tax benefits and income tax related penalties are both included in taxes on income from continuing operations. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability and deferred taxes in the period in which the facts that give rise to an adjustment become known. Pensions and other postretirement benefits: We provide a range of benefits to eligible employees and retired employees, including benefits available pursuant to pension and postretirement healthcare benefits plans. We record annual amounts relating to these plans based on calculations which include various actuarial assumptions such as discount rates, expected rates of return on plan assets, compensation increases, turnover rates and healthcare cost trend rates. We review our actuarial assumptions on an annual basis and make modifications to the assumptions based on current rates and trends when appropriate. The effect of the modifications is generally amortized over future periods. Restructuring costs: We primarily recognize employee termination benefits when payment becomes probable and reasonably estimable because they are provided under an ongoing benefit arrangement and are based on existing plans, historical experience and negotiated settlements of prior plans. Termination benefits provided under one-time termination benefits arrangements, if any, are recognized upon communication to the employee. We recognize charges ratably over the future service period if the employee is required to render service until termination. Other restructuring costs may include facility closure, employee relocation, equipment relocation and outplacement costs and are recognized in the period they are incurred. Contingent consideration related to business acquisitions: In connection with business acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified objectives such as receipt of regulatory approval, commercialization of a product or achievement of sales targets. In a business combination, we record a contingent liability, as of the acquisition date, representing the estimated fair value of the contingent consideration that we expect to pay. We remeasure the fair value of our contingent consideration arrangements each reporting period and, based on new developments, record changes in fair value until either the contingent consideration obligation is satisfied through payment upon the achievement of, or the obligation no longer exists due to the failure to achieve, the specified objectives. The change in the fair value is recorded in selling, general and administrative expenses in the consolidated statement of income. A contingent consideration payment is classified as a financing activity in the consolidated statement of cash flows to the extent it was recorded as a liability as of the acquisition date. Any additional amount paid in excess of the amount initially accrued is classified as an operating activity in the consolidated statement of cash flows. If the transaction is determined to be an asset acquisition rather than a business combination, a contingent consideration liability is recognized when the specified objective is deemed probable and is estimable. Revenue recognition: We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For the OEM segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which represented 88%, 10% and 2% of our consolidated net revenues, respectively, for the year ended December 31, 2022. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. We have made the following revenue accounting policy elections and elected to use certain practical expedients: (1) we account for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) we do not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, we expect the period between the time when we transfer a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) we expense costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) we account for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) we classify shipping and handling costs within cost of goods sold; and (6) with respect to the OEM segment, we have applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less. The amount of consideration we receive and revenue we recognize varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. Our policy is to accept returns only in cases in which the product is defective and covered under our standard warranty provisions. When we give customers the right to return products, we estimate the expected returns based on an analysis of historical experience. The liability for returns and allowances was $17.9 million and $15.2 million as of December 31, 2022 and 2021, respectively. In estimating customer rebates, we consider the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers (as we have a history of providing similar rebates on similar products to similar customers) and other relevant information. The reserve for customer incentive programs, including customer rebates, was $29.0 million and $26.4 million at December 31, 2022 and 2021, respectively. We expect the amounts subject to the reserve as of December 31, 2022 to be paid within 90 days subsequent to period-end.

Recently issued accounting stan

Recently issued accounting standards	12 Months Ended
Recently issued accounting standards	Dec. 31, 2022
Accounting Policies [Abstract]
Recently issued accounting standards	Recently issued accounting standards From time to time, new accounting guidance issued by the FASB or other standard setting bodies is adopted as of the specified effective date or, when permitted by the guidance and as determined by us, as of an earlier date. We have assessed recently issued guidance that is not yet effective and believe the new guidance that we have assessed will not have a material impact on our results of operations, cash flows or financial position.

Net revenues

Net revenues	12 Months Ended
Net revenues	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Net revenues	Net revenues The following table disaggregates revenue by global product category for the year ended December 31, 2022, 2021 and 2020. Year Ended December 31, 2022 2021 2020 Vascular access $ 683,612 $ 700,240 $ 657,703 Anesthesia 388,890 380,140 302,293 Interventional 445,018 427,500 382,435 Surgical 392,917 377,756 317,200 Interventional urology 322,832 341,661 290,022 OEM 272,624 245,681 220,246 Other (1) 285,148 336,585 367,257 Net revenues (2) $ 2,791,041 $ 2,809,563 $ 2,537,156 (1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products). Certain product lines within the respiratory product category were sold during 2021. See Note 4 for additional information related to the Respiratory business divestiture. (2) The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments includes net revenues from each of the non-OEM product categories listed above.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
Acquisitions and Divestitures	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Divestitures	Acquisitions and Divestiture On September 27, 2022, the second day of the fourth quarter, we completed the acquisition of Standard Bariatrics, Inc. (“Standard Bariatrics”), a privately-held medical device company that commercialized a powered stapling technology for bariatric surgery that complements our surgical product portfolio. The fair value of consideration transferred was $211.8 million, which included cash payments of $173.0 million and $38.8 million in estimated fair value of contingent consideration. The contingent consideration liability represents the estimated fair value of our obligations, under the acquisition agreement, to make three milestone payments up to $130 million in aggregate if certain commercial milestones are met. The milestone payments are based on net sales growth over the three-year period following the closing of the transaction. The fair value of the contingent consideration was estimated using a Monte Carlo valuation approach. See Note 12 for additional information on the fair value measurement of the contingent consideration. The acquisition was financed using borrowings under our revolving credit facility and cash on hand. The following table presents the fair value of the assets acquired and liabilities assumed with respect to the Standard Bariatrics acquisition: (Dollars in thousands) Assets Current assets $ 8,028 Property, plant and equipment 3,342 Intangible assets 154,450 Goodwill 71,420 Other assets 2,122 Total assets acquired 239,362 Less: Current liabilities 2,661 Other liabilities 24,896 Liabilities assumed 27,557 Net assets acquired $ 211,805 The goodwill resulting from the Standard Bariatrics acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired business and is not tax deductible. The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of the Standard Bariatrics acquisition: Standard Bariatrics Fair value Useful life (years) Intellectual property $ 128,300 15 Trade names 22,500 25 Customer relationships 3,650 11 For the year ended December 31, 2022, we incurred $1.3 million in transaction expenses associated with the Standard Bariatrics acquisition, which are included in selling, general and administrative expenses in the consolidated statement of income. Pro forma information for the Standard Bariatrics acquisition is not presented as the operations of Standard Bariatrics are not deemed to be significant to our overall operations. Asset Acquisition On June 13, 2022, we acquired a privately-owned catheter company for an initial cash payment of $22.8 million. Under the terms of the acquisition agreement, we may become obligated to make additional cash payments up to $26.2 million if certain commercial and revenue goals are met. The acquisition, which complements our interventional product portfolio, principally consisted of a proprietary catheter design and other related intellectual property, being amortized over a useful life of 15 years. Divestiture On May 15, 2021, we entered into a definitive agreement to sell certain product lines within our global respiratory product portfolio (the "Divested respiratory business") to Medline Industries, Inc. (“Medline”) for consideration of $286.0 million, reduced by $12.0 million in working capital not transferring to Medline, which is subject to customary post close adjustments (the "Respiratory business divestiture"). In connection with the Respiratory business divestiture, we also entered into several ancillary agreements with Medline to help facilitate the transfer of the business, which provide for transition support, quality, supply and manufacturing services, including a manufacturing and supply transition agreement (the "MSTA"). On June 28, 2021, we completed the initial phase of the Respiratory business divestiture, pursuant to which we received cash proceeds of $259.0 million. The second phase of the Respiratory business divestiture will occur once we transfer certain additional manufacturing assets to Medline. Our receipt of $15.0 million in additional cash proceeds is contingent upon the transfer of these manufacturing assets and is expected to occur prior to the end of 2023. We plan to recognize the contingent consideration, and any gain on sale resulting from the second phase of the divestiture, when it becomes realizable. Net revenues attributable to our divested respiratory business recognized prior to the Respiratory business divestiture are included within each of our geographic segments and were $60.7 million and $138.5 million for the years ended December 31, 2021 and 2020, respectively. Net revenues attributed to services provided to Medline in accordance with the MSTA, which are presented within our Americas reporting segment, were $79.1 million and $51.1 million for the years ended December 31, 2022, and 2021, respectively. Supplemental cash flow information Year Ended December 31, 2022 2021 2020 Non cash investing and financing activities of continuing operations: Acquisition of businesses $ 43,168 $ — $ —

Restructuring and impairment ch

Restructuring and impairment charges	12 Months Ended
Restructuring and impairment charges	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring and impairment charges	Restructuring and impairment charges 2022 restructuring plan On November 15, 2022, we initiated a strategic restructuring plan designed to improve operating performance and position the organization to deliver long-term durable growth by creating efficiencies that align with our high growth strategic objectives (the “2022 restructuring plan”). The plan primarily involves the relocation of certain manufacturing operations to existing lower-cost locations in addition to the streamlining of various business functions across the organization and related workforce reductions. These actions are expected to be substantially completed during 2023. The following table provides a summary of the cost estimates by major type of expense associated with the 2022 restructuring plan: Total estimated amount expected to be incurred Plan expense estimates: (Dollars in millions) Termination benefits $18 million to $22 million Other costs (1) $1 million to $1 million Restructuring Charges $19 million to $23 million Restructuring related charges (2) $20 million to $25 million Total restructuring and restructuring related charges $39 million to $48 million (1) Includes facility closure and outplacement costs. (2) Restructuring related charges represent costs that are directly related to the program and principally comprise costs to transfer manufacturing operations to the existing lower-cost locations, project management costs and accelerated depreciation. The plan also includes an $8.1 million non cash tax related charge arising from establishing a valuation allowance against a local deferred tax asset, which is no longer expected to be utilized as a result of the transfer. Excluding this tax charge, the majority of the restructuring related charges are expected to be recognized within cost of goods sold. We estimate that $26 million to $32 million of the restructuring and restructuring related charges will result in cash outlays, most of which are expected to be made in 2023. Additionally, we expect to incur approximately $2 million in aggregate capital expenditures under the plan, most of which is expected to be incurred during 2023. For the year ended December 31, 2022, we incurred $10.1 million in restructuring related charges, which were recognized in cost of goods sold and taxes on income from continuing operations. Respiratory divestiture plan During 2021 and in connection with the Respiratory business divestiture, we committed to a restructuring plan designed to separate the manufacturing operations to be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites being transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023. The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan: Total estimated amount expected to be incurred Plan expense estimates: (Dollars in millions) Restructuring charges (1) $5 million to $8 million Restructuring related charges (2) $19 million to $22 million Total restructuring and restructuring related charges $24 million to $30 million (1) Substantially all of the charges consist of employee termination benefit costs. (2) Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold. We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays. Additionally, we expect to incur $22 million to $28 million in aggregate capital expenditures under the plan. For the years ended December 31, 2022 and 2021, we incurred $8.9 million and $3.3 million, respectively, in pre-tax restructuring related charges, all of which were recognized in cost of goods sold. As of December 31, 2022, we have incurred net aggregate restructuring expenses related to the Respiratory divestiture plan of $3.3 million. Additionally, as of December 31, 2022, we have incurred net aggregate restructuring related charges in connection with the Respiratory divestiture plan of $12.2 million, which were primarily included in cost of goods sold 2019 Footprint realignment plan In February 2019, we initiated a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations and related workforce reductions (the “2019 Footprint realignment plan"). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial. 2018 Footprint realignment plan In May 2018, we initiated a restructuring plan involving the relocation of certain European manufacturing operations to existing lower-cost locations, the outsourcing of certain European distribution operations and related workforce reductions (the "2018 Footprint realignment plan"). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial. 2014 Footprint realignment plan In April 2014, we initiated a restructuring plan involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations (the "2014 Footprint realignment plan"). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial. The following table summarizes the restructuring reserve activity related to our 2022 restructuring plan, Respiratory divestiture plan as well as the 2019 and 2018 Footprint realignment plans: 2022 restructuring plan Respiratory divestiture plan 2019 Footprint realignment plan 2018 Footprint realignment plan Balance at December 31, 2020 (1) $ — $ — $ 8,054 $ 50,081 Subsequent accruals — 2,694 253 2,476 Cash payments — (7) (4,982) (4,813) Foreign currency translation and other — (86) (19) (3,679) Balance at December 31, 2021 (1) — 2,601 3,306 44,065 Subsequent accruals 15,523 578 (987) 2,076 Cash payments (978) (149) (874) (24,310) Foreign currency translation and other 315 19 — (3,292) Balance at December 31, 2022 (1) $ 14,860 $ 3,049 $ 1,445 $ 18,539 (1) The restructuring reserves as of December 31, 2022, 2021 and 2020 consisted mainly of accruals related to termination benefits. Other costs (facility closure, employee relocation, equipment relocation and outplacement costs) were expensed and paid in the same period. The restructuring and impairment charges recognized for the years ended December 31, 2022, 2021, and 2020 consisted of the following: 2022 Termination benefits Other Costs (1) Total 2022 Restructuring plan $ 15,465 $ 58 $ 15,523 Respiratory divestiture plan 504 74 578 2019 Footprint realignment plan (1,120) 133 (987) 2018 Footprint realignment plan 1,230 846 2,076 Other restructuring programs (2) 1,306 306 1,612 Total restructuring charges 17,385 1,417 18,802 Asset impairment charges — 1,497 1,497 Total restructuring and impairment charges $ 17,385 $ 2,914 $ 20,299 2021 Termination benefits Other Costs (1) Total Respiratory divestiture plan $ 2,687 $ 7 $ 2,694 2021 Restructuring plan 7,280 77 7,357 2019 Footprint realignment plan (111) 364 253 2018 Footprint realignment plan 2,335 141 2,476 Other restructuring programs (3) (429) 2,648 2,219 Total restructuring charges 11,762 3,237 14,999 Asset impairment charges — 6,739 6,739 Total restructuring and impairment charges $ 11,762 $ 9,976 $ 21,738 2020 Termination benefits Other Costs (1) Total 2020 Workforce reduction plan $ 8,494 $ 353 $ 8,847 2019 Footprint realignment plan 647 895 1,542 2018 Footprint realignment plan 5,565 383 5,948 Other restructuring programs (4) (72) 838 766 Total restructuring charges 14,634 2,469 17,103 Asset impairment charges — 21,388 21,388 Total restructuring and impairment charges $ 14,634 $ 23,857 $ 38,491 (1) Includes facility closure, contract termination and other exit costs. (2) Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities, the 2014 Footprint realignment plan and the 2020 Workforce reduction plan, a program initiated in the second quarter of 2020. (3) Includes the 2020 Workforce reduction plan and the 2014 Footprint realignment plan. (4) Includes activity primarily related to the 2016 and 2014 Footprint realignment plans. Impairment Charges For the year ended December 31, 2022, we recorded impairment charges of $1.5 million related to our decision to abandon certain assets. For the year ended December 31, 2021, we recorded impairment charges of $6.7 million related to our decision to abandon intellectual property and other assets primarily associated with our respiratory product portfolio that was not transferred to Medline as part of the Respiratory business divestiture. For the year ended December 31, 2020, we recorded impairment charges of $21.4 million related to our decision to abandon intellectual property and other assets associated with our surgical product portfolio.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories at December 31, 2022 and 2021 consist of the following: 2022 2021 Raw materials $ 186,641 $ 146,433 Work-in-process 98,993 81,503 Finished goods 292,873 249,707 Inventories $ 578,507 $ 477,643

Property, plant and equipment

Property, plant and equipment	12 Months Ended
Property, plant and equipment	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment The major classes of property, plant and equipment, at cost, at December 31, 2022 and 2021 were as follows: 2022 2021 Land, buildings and leasehold improvements $ 272,578 $ 285,305 Machinery and equipment 462,447 475,040 Computer equipment and software 192,785 191,605 Construction in progress 76,077 49,782 1,003,887 1,001,732 Less: Accumulated depreciation (556,682) (557,974) Property, plant and equipment, net $ 447,205 $ 443,758

Goodwill and other intangible a

Goodwill and other intangible assets	12 Months Ended
Goodwill and other intangible assets	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Changes in the carrying amount of goodwill, by reportable operating segment, for the years ended December 31, 2022 and 2021 were as follows: Americas EMEA Asia OEM Total Balance as of December 31, 2020 Goodwill $ 2,032,410 $ 536,228 $ 237,446 $ 112,010 $ 2,918,094 Accumulated impairment losses (332,128) — — — (332,128) 1,700,282 536,228 237,446 112,010 2,585,966 Goodwill disposed (21,802) (7,537) (6,406) — (35,745) Goodwill related to acquisitions (1,560) (232) (163) — (1,955) Translation and other adjustments (696) (36,310) (7,058) — (44,064) Balance as of December 31, 2021 1,676,224 492,149 223,819 112,010 2,504,202 Goodwill related to acquisitions 53,970 7,281 10,169 — 71,420 Translation and other adjustments 899 (30,906) (8,885) — (38,892) Balance as of December 31, 2022 $ 1,731,093 $ 468,524 $ 225,103 $ 112,010 $ 2,536,730 Intangible assets at December 31, 2022 and 2021 consisted of the following: Gross Carrying Amount Accumulated Amortization 2022 2021 2022 2021 Customer relationships $ 1,328,539 $ 1,328,611 $ (497,335) $ (441,059) In-process research and development 27,075 28,158 — — Intellectual property 1,599,355 1,440,643 (646,643) (560,740) Distribution rights 23,115 23,434 (21,090) (20,630) Trade names 564,023 549,269 (71,128) (59,249) Non-compete agreements 21,429 22,783 (21,175) (22,153) $ 3,563,536 $ 3,392,898 $ (1,257,371) $ (1,103,831) As of December 31, 2022, trade names having a carrying value of $230.3 million are considered indefinite-lived. Acquired IPR&D is indefinite-lived until the completion of the related development project, at which point amortization of the carrying value of the technology will commence. Amortization expense related to intangible assets was $164.1 million, $165.6 million, and $158.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. The estimated annual amortization expense for each of the five succeeding years is as follows: 2023 $ 167,100 2024 165,000 2025 164,100 2026 161,300 2027 158,100

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2022
Leases [Abstract]
Leases	Leases We have operating leases for various types of properties, consisting of manufacturing plants, engineering and research centers, distribution warehouses, offices and other facilities, and equipment used in operations. Some leases provide us with an option, exercisable at our sole discretion, to terminate the lease or extend the lease term for one Maturities of lease liabilities December 31, 2022 2023 $ 24,613 2024 21,483 2025 19,884 2026 19,206 2027 18,338 2028 and thereafter 63,242 Total lease payments 166,766 Less: interest (26,872) Present value of lease liabilities $ 139,894 Supplemental information December 31, 2022 December 31, 2021 Total lease liabilities (1) $ 139,894 $ 138,163 Cash paid for amounts included in the measurement of lease liabilities within operating cash flows $ 28,308 $ 29,199 Right of use assets obtained in exchange for operating lease obligations $ 25,202 $ 55,290 Weighted average remaining lease term 7.9 years 7.9 years Weighted average discount rate 4.2 % 3.7 % (1) The current portion of the operating lease liability is included in other current liabilities .

Borrowings

Borrowings	12 Months Ended
Borrowings	Dec. 31, 2022
Debt Disclosure [Abstract]
Borrowings	Borrowings Our borrowings at December 31, 2022 and 2021 were as follows: 2022 2021 Senior Credit Facility: Revolving credit facility, at a rate of 5.80% at December 31, 2022, and 1.48% at December 31, 2021, due 2027 $ 148,250 $ 141,000 Term loan facility, at a rate of 5.80% at December 31, 2022 and 1.48% at December 31 2021, due 2027 500,000 647,500 4.625% Senior Notes due 2027 500,000 500,000 4.25% Senior Notes due 2028 500,000 500,000 Securitization program, at a rate of 5.11% at December 31, 2022 and 1.00% at December 31, 2021 75,000 75,000 1,723,250 1,863,500 Less: Unamortized debt issuance costs (11,727) (13,398) 1,711,523 1,850,102 Current portion of borrowings (87,500) (110,000) Long-term borrowings $ 1,624,023 $ 1,740,102 Senior credit facility On November 4, 2022, we amended and restated our existing credit agreement by entering into a Third Amended and Restated Credit Agreement (the “Credit Agreement”) which provides for a five-year revolving credit facility of $1.0 billion and a term loan facility of $500.0 million. The obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of our material domestic subsidiaries. The obligations under the Credit Agreement are secured, subject to certain exceptions and limitations, by a lien on substantially all of the assets owned by us and each guarantor. The maturity date of the revolving credit facility and the term loan facility under the Credit Agreement is November 4, 2027. At our option, loans under the Credit Agreement will bear interest at a rate equal to adjusted Term SOFR plus an applicable margin ranging from 1.125% to 2.00% or at an alternate base rate, which is defined as the highest of (i) the “Prime Rate” in the U.S. last quoted by The Wall Street Journal, (ii) 0.50% above the greater of the federal funds rate and the rate comprised of both overnight federal funds and overnight eurodollar transactions denominated in Dollars and (iii) 1.00% above the Term SOFR Rate for a one month interest period, plus an applicable margin ranging from 0.125% to 1.00%, in each case subject to adjustments based on our total net leverage ratio. Overdue loans will bear interest at the rate otherwise applicable to such loans plus 2.00%. The obligations to extend credit under the Credit Agreement are subject to customary conditions for transactions of this type. The Credit Agreement contains customary representations and warranties and covenants that, in each case, subject to certain exceptions, qualifications and thresholds, (a) place limitations on us and our subsidiaries regarding the incurrence of additional indebtedness, additional liens, fundamental changes, dispositions of property, investments and acquisitions, dividends and other restricted payments, transactions with affiliates, restrictive agreements, changes in lines of business and swap agreements, and (b) require us and our subsidiaries to comply with sanction laws and other laws and agreements, to deliver financial information and certain other information and give notice of certain events, to maintain their existence and good standing, to pay their other obligations, to permit the administrative agent and the lenders to inspect their books and property, to use the proceeds of the Credit Agreement only for certain permitted purposes and to provide collateral in the future. Subject to certain exceptions, we are required to maintain a maximum total net leverage ratio of 4.50 to 1.00. We are further required to maintain a minimum interest coverage ratio of 3.50 to 1.00. We capitalized transaction fees of $4.7 million, including underwriters' discounts and commissions, incurred in connection with the third amendment to the Credit Agreement. Additionally, we recognized a loss on extinguishment of debt of $0.5 million due to the write off of unamortized deferring financing costs. 4.625% Senior notes due 2027 In 2017, we issued $500.0 million of 4.625% Senior Notes due 2027 (the "2027 Notes"). We pay interest on the 2027 Notes semi-annually on May 15 and November 15, commencing on May 15, 2018, at a rate of 4.625% per year. The 2027 Notes mature on November 15, 2027 unless earlier redeemed by us at our option, as described below, or purchased by us at the holder’s option under specified circumstances following a Change of Control or Asset Sale (each as defined in the indenture related to the 2027 Notes), coupled with a downgrade in the ratings of the 2027 Notes, or upon our election to exercise our optional redemption rights, as described below. We incurred transaction fees of $7.9 million, including underwriters’ discounts and commissions, in connection with the offering of the 2027 Notes, which were recorded on the consolidated balance sheet as a reduction to long-term borrowings and are being amortized over the term of the 2027 Notes. We used the net proceeds from the offering to repay borrowings under our revolving credit facility. Our obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, by each of our existing and future 100% owned domestic subsidiaries that is a guarantor or other obligor under the Credit Agreement and by certain of our other 100% owned domestic subsidiaries. As of November 15, 2022, we became entitled, on one or more occasions, to redeem some or all of the 2027 Notes at a redemption price of 102.313% of the principal amount of the 2027 Notes subject to redemption, declining, in annual increments of 0.771%, to 100% of the principal amount on November 15, 2025, plus accrued and unpaid interest. Prior to November 15, 2022, our redemption rights, which we did not exercise, were subject to different terms. The indenture relating to the 2027 Notes contains covenants that, among other things and subject to certain exceptions, limit or restrict our ability to create liens; merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; or enter into sale leaseback transactions. 4.25% Senior Notes due 2028 In 2020, we issued $500.0 million of 4.25% Senior Notes due 2028 (the "2028 Notes"). We pay interest on the 2028 Notes semi-annually on June 1 and December 1, commencing on December 1, 2020, at a rate of 4.25% per year. The 2028 Notes mature on June 1, 2028 unless earlier redeemed at our option, as described below, or purchased at the holder’s option under specified circumstances following a Change of Control or Event of Default (each as defined in the indenture related to the 2028 Notes), coupled with a downgrade in the ratings of the 2028 Notes, or upon our election to exercise its optional redemption rights, as described below. We incurred transaction fees of $8.5 million, including underwriters’ discounts and commissions, in connection with the offering of the 2028 Notes, which were recorded on the consolidated balance sheet as a reduction to long-term borrowings and are being amortized over the term of the 2028 Notes. We used the net proceeds from the offering to repay borrowings under our revolving credit facility. Our obligations under the 2028 Notes are fully and unconditionally guaranteed, jointly and severally, by each of our existing and future 100% owned domestic subsidiaries that is a guarantor or other obligor under the Credit Agreement and by certain of our other 100% owned domestic subsidiaries. At any time on or after June 1, 2023, we may, on one or more occasions, redeem some or all of the 2028 Notes at a redemption price of 102.125% of the principal amount of the 2028 Notes subject to redemption, declining, in annual increments of 1.0625%, to 100% of the principal amount on June 1, 2025, plus accrued and unpaid interest. In addition, at any time prior to June 1, 2023, we may, on one or more occasions, redeem some or all of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes redeemed, plus a “make-whole” premium and any accrued and unpaid interest. The “make-whole” premium is the greater of (a) 1.0% of the principal amount of the 2028 Notes subject to redemption or (b) the excess, if any, over the principal amount of the 2028 Notes, of the present value, on the redemption date, of the sum of (i) the June 1, 2023, optional redemption price plus (ii) all required interest payments on the 2028 Notes through June 1, 2023, (other than accrued and unpaid interest to the redemption date), generally computed using a discount rate equal to the yield to maturity of U.S. Treasury securities with a constant maturity for the period most nearly equal to the period from the redemption date to June 1, 2023 (unless the period is less than one year, in which case the weekly average yield on traded U.S. Treasury securities adjusted to a constant maturity of one year will be used), plus 50 basis points. In addition, at any time prior to June 1, 2023, we may, on one or more occasions, redeem up to 40% of the aggregate principal amount of the 2028 Notes, using the proceeds of specified types of our equity offerings and subject to specified conditions, at a redemption price equal to 104.25% of the principal amount of the Notes redeemed, plus accrued and unpaid interest. The indenture relating to the 2028 Notes contains covenants that, among other things, limit or restrict our ability, and the ability of our subsidiaries, to create liens; merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; and enter into sale leaseback transactions. Securitization program We have an accounts receivable securitization facility under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of Teleflex. Accordingly, the assets of the SPE are not available to satisfy the obligations of Teleflex or any of its subsidiaries. The SPE sells undivided interests in those receivables to an asset backed commercial paper conduit for consideration of up to the maximum available capacity. This facility is utilized from time to time to provide increased flexibility in funding short term working capital requirements. The agreement governing the accounts receivable securitization facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this facility may give rise to the right of its counterparty to terminate this facility. As of December 31, 2022, we were in compliance with the covenants, and none of the termination events had occurred. As of December 31, 2022 and 2021, we had $75.0 million (the maximum amount available) of outstanding borrowings under our accounts receivable securitization facility. Fair value of long-term debt To determine the fair value of our debt for which quoted prices are not available, we use a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. Our implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of our debt as of December 31, 2022 and 2021, which is valued based on Level 2 inputs within the hierarchy used to measure fair value (see Note 12 to the consolidated financial statements for further information): December 31, 2022 December 31, 2021 Fair value of debt $ 1,674,232 $ 1,893,518 Debt Maturities As of December 31, 2022, the aggregate amounts of long-term debt, demand loans and debt under our securitization program that will mature during each of the next four years and thereafter were as follows: 2023 $ 87,500 2024 12,500 2025 25,000 2026 25,000 2027 and thereafter 1,573,250 Supplemental cash flow information Year Ended December 31, 2022 2021 2020 Cash interest paid $ 70,918 $ 73,598 $ 79,533

Financial instruments

Financial instruments	12 Months Ended
Financial instruments	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial instruments Foreign currency forward contracts We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flows hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We enter into the non-designated foreign currency forward contracts for periods consistent with the currency exposures, which generally approximate one month. For the years ended December 31, 2022 and 2021, we recognized losses related to non-designated foreign currency forward contracts of $3.0 million and $8.9 million, respectively. The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of December 31, 2022 and 2021 was $184.8 million and $149.5 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of December 31, 2022 and 2021 was $152.9 million and $161.2 million, respectively. All open foreign currency forward contracts as of December 31, 2022 have durations of 12 months or less. Cross-currency interest rate swaps During 2019, we entered into cross-currency swap agreements with five different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $250 million at an annual interest rate of 4.8750% for €219.2 million at an annual interest rate of 2.4595%. The swap agreements are designed as net investment hedges and expire on March 4, 2024. During 2018, we entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements are designated as net investment hedges and expire on October 4, 2023. The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement. The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI") while the accrued interest is recognized in interest expense in the statement of operations. The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the year ended December 31, 2022 and December 31, 2021: December 31, 2022 December 31, 2021 Foreign exchange gains $ 22,399 $ 34,849 Interest benefit 20,880 19,296 Balance sheet presentation The following table presents the locations in the consolidated balance sheets and fair value of derivative instruments as of December 31, 2022 and 2021: December 31, 2022 December 31, 2021 Asset derivatives: Designated foreign currency forward contracts $ 3,154 $ 1,957 Non-designated foreign currency forward contracts 41 56 Cross-currency interest rate swap 48,503 21,718 Prepaid expenses and other current assets 51,698 23,731 Cross-currency interest rate swap 11,912 9,560 Other assets 11,912 9,560 Total asset derivatives $ 63,610 $ 33,291 Liability derivatives: Designated foreign currency forward contracts $ 983 $ 993 Non-designated foreign currency forward contracts 477 147 Other current liabilities 1,460 1,140 Total liability derivatives $ 1,460 $ 1,140 See Note 13 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax.

Fair value measurement

Fair value measurement	12 Months Ended
Fair value measurement	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement Fair value is the price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. Under GAAP, there is a three-level hierarchy of the inputs (i.e., assumptions that market participants would use in pricing an asset or liability) used to measure fair value. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the entire fair value measurement. The levels of inputs within the hierarchy used to measure fair value are as follows: Level 1 — inputs to the fair value measurement that are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 — inputs to the fair value measurement that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 — inputs to the fair value measurement that are unobservable inputs for the asset or liability. The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 and 2021: Basis of fair value measurement December 31, 2022 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 10,097 $ 10,097 $ — $ — Derivative assets 63,610 — 63,610 — Derivative liabilities 1,460 — 1,460 — Contingent consideration liabilities 44,022 — — 44,022 Basis of fair value measurement December 31, 2021 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 19,186 $ 19,186 $ — $ — Derivative assets 33,291 — 33,291 — Derivative liabilities 1,140 — 1,140 — Contingent consideration liabilities 9,814 — — 9,814 There were no transfers of financial assets or liabilities into or out of Level 3 within the fair value hierarchy during the years ended December 31, 2022 or 2021. Valuation Techniques Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forward contracts and cross-currency interest rate swap agreements to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forward and cross-currency swap agreements by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties. Our financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to our acquisitions. Contingent consideration Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including revenue growth rates (based on internal operational budgets and long-range strategic plans), revenue volatility, discount rates, probability of payment and projected payment dates. We determine the fair value of certain contingent consideration liabilities using a Monte Carlo simulation (which involves a simulation of future revenues during the earn-out period using management's best estimates) or discounted cash flow analysis. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. As of December 31, 2022, the maximum amount we could be required to pay under the contingent consideration arrangements related to the Standard Bariatrics acquisition was $130.0 million. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities. Contingent Consideration Liability Valuation Technique Unobservable Input Revenue-based Monte Carlo simulation Revenue volatility 31.8 % Risk free rate Cost of debt structure Projected year of payment 2024 - 2026 The following table provides information regarding changes in our contingent consideration liabilities for the years ended December 31, 2022 and 2021: Contingent consideration 2022 2021 Beginning balance – January 1 $ 9,814 $ 36,633 Initial estimate upon acquisition 38,800 — Payments (6,975) (31,678) Revaluations and other adjustments 2,350 4,895 Translation adjustment 33 (36) Ending balance – December 31 $ 44,022 $ 9,814

Shareholders' equity

Shareholders' equity	12 Months Ended
Shareholders' equity	Dec. 31, 2022
Equity [Abstract]
Shareholders' equity	Shareholders' equity Our authorized capital is comprised of 200 million common shares, $1 par value, and 500,000 preference shares. No preference shares have been outstanding during the last three years. Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average shares outstanding: 2022 2021 2020 Basic 46,898 46,774 46,488 Dilutive effect of share based awards 411 653 799 Diluted 47,309 47,427 47,287 Weighted average shares that were antidilutive and therefore excluded from the calculation of diluted earnings per share were 0.5 million for the year ended December 31, 2022, and 0.1 million for the years ended December 31, 2021 and 2020. The following tables provides information relating to the changes in accumulated other comprehensive income (loss), net of tax, for each of the years ended December 31, 2022 and 2021: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2020 $ (482) $ (150,257) $ (146,559) $ (297,298) Other comprehensive income (loss) before reclassifications 351 6,192 (63,191) (56,648) Amounts reclassified from accumulated other comprehensive income 1,212 5,775 — 6,987 Net current-year other comprehensive income (loss) 1,563 11,967 (63,191) (49,661) Balance at December 31, 2021 1,081 (138,290) (209,750) (346,959) Other comprehensive income (loss) before reclassifications 7,179 (2,606) (62,904) (58,331) Amounts reclassified from accumulated other comprehensive income (3,329) 5,097 — 1,768 Net current-year other comprehensive income (loss) 3,850 2,491 (62,904) (56,563) Balance at December 31, 2022 $ 4,931 $ (135,799) $ (272,654) $ (403,522) The following table provides information relating to the (gains) losses recognized in the statements of income including the reclassifications of losses (gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the years ended December 31, 2022, 2021 and 2020: Year Ended December 31, 2022 2021 2020 (Gains) losses on designated foreign exchange forward contracts: Cost of goods sold $ (3,532) $ 1,150 $ 2,354 Total before tax (3,532) 1,150 2,354 Taxes expense (benefit) 203 62 (240) Net of tax $ (3,329) $ 1,212 $ 2,114 Amortization of pension and other postretirement benefits items: Actuarial losses (1) $ 7,660 $ 8,543 $ 7,253 Prior-service credits (1) (1,017) (1,012) 33 Total before tax 6,643 7,531 7,286 Tax benefit (1,546) (1,756) (1,701) Net of tax $ 5,097 $ 5,775 $ 5,585 Impact on income from continuing operations, net of tax $ 1,768 $ 6,987 $ 7,699 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 16 for additional information).

Stock compensation plans

Stock compensation plans	12 Months Ended
Stock compensation plans	Dec. 31, 2022
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Stock compensation plans	Stock compensation plans In May 2014, our stockholders approved the Teleflex Incorporated 2014 Stock Incentive Plan (the "Plan"). The Plan provides for several different kinds of awards, including stock options, stock appreciation rights, stock awards and other stock-based awards to directors, officers and key employees. Under the Plan, we are authorized to issue up to 5.3 million shares of common stock, subject to adjustment in accordance with special share counting rules in the Plan. Options granted under the Plan have an exercise price equal to the closing price of the common stock on the date of the grant. In 2022, we granted, under the Plan, non-qualified options to purchase 156,918 shares of common stock and granted restricted stock units relating to 85,780 shares of common stock under the Plan. We also granted performance share units (“PSUs”), as described in the following paragraph. In 2018, we began granting PSUs to specified senior managers. The PSUs are designed to provide further incentive to our senior management with respect to the achievement of our long term financial objectives. The PSU component of the equity incentive program is designed to provide shares of our common stock to the holder based upon our achievement of certain financial performance criteria during a designated performance period of three years. The number of shares to be awarded under the PSUs granted are subject to modification based upon our total stockholder return relative to a designated group of public companies. Assuming target performance is achieved, a total of 25,131 shares of common stock would be issuable in respect of the PSUs granted and a maximum of 62,927 shares would be issuable in respect of such PSUs upon achievement of maximum performance levels.The following table summarizes the share-based compensation activity: 2022 2021 2020 Share-based compensation expense $ 27,224 $ 22,937 $ 20,739 Total income tax benefit recognized for share-based compensation arrangements 6,824 10,912 21,958 Net excess tax benefit 1,292 6,355 17,549 The unrecognized compensation expense for all awards granted in 2022 as of the grant date was $45.0 million, which will be recognized over the vesting period of the awards. As of December 31, 2022, 2,843,121 shares were available for future grants under the Plan. Option Awards The fair value of options granted in 2022, 2021 and 2020 was estimated at the date of grant using a Black-Scholes option pricing model. The following weighted-average assumptions were used: 2022 2021 2020 Risk-free interest rate 1.56 % 0.67 % 1.16 % Expected life of option 5.03 years 5.01 years 5.00 years Expected dividend yield 0.41 % 0.34 % 0.39 % Expected volatility 30.09 % 30.03 % 23.98 % The following table summarizes the option activity during 2022: Shares Subject to Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding, beginning of the year 1,107,999 $ 214.13 Granted 156,918 330.03 Exercised (27,518) 95.07 Forfeited or expired (8,551) 359.54 Outstanding, end of the year 1,228,848 230.58 4.77 $ 66,774 Exercisable, end of the year 990,842 $ 201.19 3.84 $ 66,746 The weighted average grant date fair value for options granted during 2022, 2021 and 2020 was $88.92, $103.87 and $74.60, respectively. The total intrinsic value of options exercised during 2022, 2021 and 2020 was $5.0 million, $27.4 million and $77.9 million, respectively. We recorded $10.3 million of expense related to options during 2022, which is included in cost of goods sold or selling, general and administrative expenses. As of December 31, 2022, the unamortized share-based compensation cost related to non-vested stock options, net of expected forfeitures, was $12.2 million, which is expected to be recognized over a weighted-average period of 1.65 years. Authorized but unissued shares of our common stock are issued upon exercises of options. Stock Awards The fair value of PSUs granted were determined using a Monte Carlo simulation valuation model. The grant date fair value for the 2022 awards was $301.00. The fair value for restricted stock units granted in 2022, 2021 and 2020 was estimated at the date of grant based on the market price for the underlying stock on the grant date discounted for the risk free interest rate and the present value of expected dividends over the vesting period. The following weighted-average assumptions were used: 2022 2021 2020 Risk-free interest rate 1.57 % 0.28 % 1.07 % Expected dividend yield 0.42 % 0.34 % 0.38 % The following table summarizes the non-vested restricted stock unit activity during 2022: Number of Non-Vested Shares Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding, beginning of the year 135,378 $ 343.89 Granted 85,780 323.35 Vested (51,831) 290.75 Forfeited (21,359) 352.06 Outstanding, end of the year 147,968 $ 349.42 1.5 $ 36,970 We issued 85,780, 59,210 and 52,464 of non-vested restricted stock units in 2022, 2021 and 2020, respectively, the majority of which provide for vesting as to all underlying shares on the third anniversary of the grant date. The weighted average grant-date fair value for non-vested restricted stock units granted during 2022, 2021 and 2020 was $323.35, $398.59 and $344.70, respectively.

Income taxes

Income taxes	12 Months Ended
Income taxes	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The following table summarizes the components of the provision for income taxes from continuing operations: 2022 2021 2020 Current: Federal $ 32,798 $ 134,336 $ 11,148 State 8,747 16,970 9,644 Non-U.S. 56,442 35,399 35,042 Deferred: Federal (27,528) (85,272) (9,475) State 10,116 (16,933) (13,734) Non-U.S. 2,428 (10,151) (10,694) $ 83,003 $ 74,349 $ 21,931 At December 31, 2022, the cumulative unremitted earnings of subsidiaries outside the U.S. that are considered non-permanently reinvested and for which taxes have been provided approximated $1.1 billion. At December 31, 2022, the cumulative unremitted earnings of subsidiaries outside the U.S. that are considered permanently reinvested approximated $1.2 billion. Earnings considered permanently reinvested are expected to be reinvested indefinitely and, as a result, no additional deferred tax liability has been recognized with regard to these earnings. It is not practical to determine the deferred income tax liability on these earnings if, in the future, they are remitted to the U.S. because the income tax liability to be incurred, if any, is dependent on circumstances existing when remittance occurs. The following table summarizes the U.S. and non-U.S. components of income from continuing operations before taxes: 2022 2021 2020 U.S. $ 164,151 $ 209,231 $ 233,034 Non-U.S. 281,768 350,237 124,698 $ 445,919 $ 559,468 $ 357,732 Reconciliations between the statutory federal income tax rate and the effective income tax rate are as follows: 2022 2021 2020 Federal statutory rate 21.0 % 21.0 % 21.0 % Tax effect of international items (4.6) (6.0) (5.3) Foreign merger - deferred taxes — — — Excess tax benefits related to share-based compensation (0.3) (1.1) (4.9) State taxes, net of federal benefit 3.4 0.1 (0.3) Uncertain tax contingencies (0.4) (0.1) (0.5) Contingent consideration 0.1 0.2 (2.2) Intellectual property impairment charge — — (1.2) Research and development tax credit (1.0) (0.8) (1.1) Other, net 0.5 — 0.6 18.6 % 13.3 % 6.1 % The effective income tax rate for 2022 was 18.6% compared to 13.3% for 2021. The effective income tax rate for 2022 reflects tax expense resulting from a deferred charge relating to the 2022 Restructuring Plan and from a U.S. law effective in 2022 requiring capitalization of certain research and development expenditures. The effective income tax rate for 2021 reflects tax expense associated with the Respiratory business divestiture. Additionally, the effective tax rates for both 2022 and 2021 reflect a net excess tax benefit related to share-based compensation and a tax benefit from research and development tax credits. We are routinely subject to examinations by various taxing authorities. In conjunction with these examinations and as a regular practice, we establish and adjust reserves with respect to its uncertain tax positions to address developments related to those positions. We realized a net benefit of $2.0 million, $0.8 million and $1.7 million in 2022, 2021 and 2020 respectively, as a result of reducing our reserves with respect to uncertain tax positions, principally due to the expiration of a number of applicable statutes of limitations. The following table summarizes significant components of our deferred tax assets and liabilities at December 31, 2022 and 2021: 2022 2021 Deferred tax assets: Tax loss and credit carryforwards $ 110,857 $ 168,113 Lease Liabilities 32,339 32,127 Pension 1,163 350 Reserves and accruals 64,498 64,421 Other 24,013 4,379 Less: valuation allowances (91,531) (143,177) Total deferred tax assets 141,339 126,213 Deferred tax liabilities: Property, plant and equipment 25,427 24,479 Intangibles — stock acquisitions 379,298 352,139 Unremitted non-U.S. earnings 67,833 73,385 Lease Assets 32,339 32,127 Other 18,926 7,387 Total deferred tax liabilities 523,823 489,517 Net deferred tax liability $ (382,484) $ (363,304) Under the tax laws of various jurisdictions in which we operate, deductions or credits that cannot be fully utilized for tax purposes during the current year may be carried forward, subject to statutory limitations, to reduce taxable income or taxes payable in a future tax year. At December 31, 2022, the tax effect of such carryforwards approximated $110.9 million. Of this amount, $16.0 million has no expiration date, $20.1 million expires after 2022 but before the end of 2027 and $74.8 million expires after 2027. A portion of these carryforwards consists of tax losses and credits obtained by us as a result of acquisitions; the utilization of these carryforwards is subject to an annual limitation imposed by Section 382 of the Internal Revenue Code, which limits a company’s ability to deduct prior net operating losses following a more than 50 percent change in ownership. It is not expected that the Section 382 limitation will prevent us ultimately from utilizing the applicable loss carryforwards. The determination of state net operating loss carryforwards is dependent upon the U.S. subsidiaries’ taxable income or loss, the state’s proportion of each subsidiary's taxable net income and the application of state laws, which can change from year to year and impact the amount of such carryforward. The valuation allowance for deferred tax assets of $91.5 million and $143.2 million at December 31, 2022 and 2021, respectively, relates principally to the uncertainty of our ability to utilize certain deferred tax assets, primarily tax loss and credit carryforwards in various jurisdictions. The valuation allowance was calculated in accordance with applicable accounting standards, which require that a valuation allowance be established and maintained when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. Uncertain Tax Positions : The following table is a reconciliation of the beginning and ending balances for liabilities associated with unrecognized tax benefits for the years ended December 31, 2022, 2021 and 2020: 2022 2021 2020 Balance at January 1 $ 6,105 $ 7,230 $ 7,561 Increase in unrecognized tax benefits related to prior years 215 — 1,286 Decrease in unrecognized tax benefits related to prior years (761) — — Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations (1,117) (956) (1,864) (Decrease) increase in unrecognized tax benefits due to foreign currency translation (182) (169) 247 Balance at December 31 $ 4,260 $ 6,105 $ 7,230 The total liabilities associated with the unrecognized tax benefits that, if recognized, would impact the effective tax rate for continuing operations, were $2.7 million at December 31, 2022. We accrue interest and penalties associated with unrecognized tax benefits in income tax expense in the consolidated statements of income, and the corresponding liability is included in the consolidated balance sheets. The net interest expense (benefit) and penalties reflected in income from continuing operations for the year ended December 31, 2022 was $0.2 million and $(0.2) million, respectively; for the year ended December 31, 2021 was $0.2 million and $(0.3) million, respectively; and for the year ended December 31, 2020 was $0.2 million and $(0.5) million, respectively. The liabilities in the consolidated balance sheets for interest and penalties at December 31, 2022 were $0.6 million and $1.5 million, respectively, and at December 31, 2021 were $0.8 million and $1.8 million, respectively. The taxable years for which the applicable statute of limitations remains open by major tax jurisdictions are as follows: Beginning Ending U.S. 2019 2022 Canada 2018 2022 China 2017 2022 Czech Republic 2019 2022 France 2019 2022 Germany 2011 2022 India 2002 2022 Ireland 2018 2022 Italy 2017 2022 Malaysia 2015 2022 Singapore 2018 2022 We are routinely subject to income tax examinations by various taxing authorities. As of December 31, 2022, the most significant tax examinations in process were in Ireland, Germany and France. The date at which these examinations may be concluded and the ultimate outcome of the examinations are uncertain. As a result of the uncertain outcome of these ongoing examinations, future examinations or the expiration of statutes of limitation, it is reasonably possible that the related unrecognized tax benefits for tax positions taken could materially change from those recorded as liabilities at December 31, 2022. Due to the potential for resolution of certain examinations, and the expiration of various statutes of limitations, it is reasonably possible that our unrecognized tax benefits may change within the next year by a range of zero to $2.0 million. Supplemental cash flow information Year Ended December 31, 2022 2021 2020 Income taxes paid, net of refunds $ 162,046 $ 108,609 $ 77,163

Pension and other postretiremen

Pension and other postretirement benefits	12 Months Ended
Pension and other postretirement benefits	Dec. 31, 2022
Retirement Benefits [Abstract]
Pension and other postretirement benefits	Pension and other postretirement benefits We have a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. Our funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. As of December 31, 2022, no further benefits are being accrued under the U.S. defined benefit pension plans and the other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. Teleflex and certain of our subsidiaries provide medical, dental and life insurance benefits to pensioners or their survivors. The associated plans are unfunded and approved claims are paid from our funds. The following table provides information regarding the components of the net benefit (income) expense of the pension and postretirement benefit plans for the years ended December 31, 2022, 2021 and 2020: Pension Other Benefits 2022 2021 2020 2022 2021 2020 Service cost $ 1,346 $ 1,467 $ 1,416 $ — $ — $ — Interest cost 10,776 9,272 12,827 477 418 902 Expected return on plan assets (25,776) (30,726) (31,650) — — — Net amortization and deferral 7,900 8,589 7,447 (1,258) (1,058) (161) Net benefit (income) expense $ (5,754) $ (11,398) $ (9,960) $ (781) $ (640) $ 741 Net benefit (income) expense is primarily included in selling, general and administrative expenses within the consolidated statements of income. The following table provides the weighted average assumptions for U.S. and foreign plans used in determining net benefit cost: Pension Other Benefits 2022 2021 2020 2022 2021 2020 Discount rate 2.8 % 2.5 % 3.2 % 2.7 % 2.3 % 3.1 % Rate of return 5.6 % 6.7 % 7.5 % Initial healthcare trend rate 6.4 % 6.8 % 7.0 % Ultimate healthcare trend rate 4.5 % 4.5 % 5.0 % The following table provides summarized information with respect to the pension and postretirement benefit plans, measured as of December 31, 2022 and 2021: Pension Other Benefits 2022 2021 2022 2021 Benefit obligation, beginning of year $ 474,674 $ 501,347 $ 26,804 $ 31,921 Service cost 1,346 1,467 — — Interest cost 10,776 9,272 477 418 Actuarial (gain) loss (104,558) (13,567) (6,223) (2,288) Currency translation (3,030) (1,726) — — Benefits paid (21,472) (21,138) (2,491) (3,303) Medicare Part D reimbursement — — 53 56 Administrative costs (979) (981) — — Projected benefit obligation, end of year 356,757 474,674 18,620 26,804 Fair value of plan assets, beginning of year 469,793 457,626 Actual return on plan assets (89,506) 22,124 Contributions 1,464 12,159 Benefits paid (21,472) (21,138) Administrative costs (979) (981) Currency translation (2,030) 3 Fair value of plan assets, end of year 357,270 469,793 Funded status, end of year $ 513 $ (4,881) $ (18,620) $ (26,804) The actuarial gain for pension for the year ended December 31, 2022 was primarily due to an increase in the discount rate used to measure the obligation. The actuarial gain for pension for the year ended December 31, 2021 was primarily due to an increase in the discount rate used to measure the obligation, partially offset by decreases from changes in census data and mortality assumptions. The accumulated benefit obligations (ABO) and the projected benefit obligations (PBO) for plans with ABO and PBO in excess of plan assets were $345.5 million and $346.0 million, respectively, at December 31, 2022 and $456.0 million and $456.6 million respectively, at December 31, 2021. The fair value of plan assets for plans with PBO and ABO in excess of plan assets were $345.7 million and $449.8 million, respectively, at December 31, 2022 and December 31, 2021, respectively. The following table sets forth the amounts recognized in the consolidated balance sheet with respect to the pension and postretirement plans: Pension Other Benefits 2022 2021 2022 2021 Other assets $ 16,870 $ 17,827 $ — $ — Payroll and benefit-related liabilities (1,408) (1,602) (2,175) (2,725) Pension and postretirement benefit liabilities (14,949) (21,106) (16,445) (24,079) Accumulated other comprehensive loss (gain) 219,555 218,139 (7,812) (2,847) $ 220,068 $ 213,258 $ (26,432) $ (29,651) The following tables set forth the amounts recognized in accumulated other comprehensive income with respect to the plans: Pension Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2020 $ 205 $ 232,335 $ (80,657) $ 151,883 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (5) (8,584) 1,999 (6,590) Amounts arising during the period: Actuarial changes in benefit obligation — (4,965) 1,148 (3,817) Impact of currency translation — (847) 237 (610) Balance at December 31, 2021 200 217,939 (77,273) 140,866 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral — (7,900) 1,832 (6,068) Amounts arising during the period: Actuarial changes in benefit obligation — 10,724 (2,271) 8,453 Impact of currency translation — (1,408) 365 (1,043) Balance at December 31, 2022 $ 200 $ 219,355 $ (77,347) $ 142,208 Other Benefits Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2020 $ (4,669) $ 3,052 $ (9) $ (1,626) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,017 41 (243) 815 Amounts arising during the period: Actuarial changes in benefit obligation — (2,288) 523 (1,765) Balance at December 31, 2021 (3,652) 805 271 (2,576) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,017 241 (287) 971 Amounts arising during the period: Actuarial changes in benefit obligation — (6,223) 1,419 (4,804) Balance at December 31, 2022 $ (2,635) $ (5,177) $ 1,403 $ (6,409) The following table provides the weighted average assumptions for U.S. and foreign plans used in determining benefit obligations: Pension Other Benefits 2022 2021 2022 2021 Discount rate 5.1 % 2.8 % 5.1 % 2.7 % Rate of compensation increase 3.0 % 2.8 % Initial healthcare trend rate 5.9 % 6.0 % Ultimate healthcare trend rate 4.5 % 4.5 % The discount rate represents the interest rate used to determine the present value of future cash flows currently expected to be required to settle the pension and other benefit obligations. The weighted average discount rates for U.S. pension plans and other benefit plans of 5.20% and 5.13%, respectively, were established by comparing the projection of expected benefit payments to the AA Above Median yield curve as of December 31, 2022. The expected benefit payments are discounted by each corresponding discount rate on the yield curve. For payments beyond 30 years, we extend the curve assuming that the discount rate derived in year 30 is extended to the end of the plan’s payment expectations. Once the present value of the string of benefit payments is established, we determine the single rate on the yield curve that, when applied to all obligations of the plan, will exactly match the previously determined present value. As part of the evaluation of pension and other postretirement assumptions, we applied assumptions for mortality and healthcare cost trends that incorporate generational white and blue collar mortality trends. In determining its benefit obligations, we used generational tables that take into consideration increases in plan participant longevity. Our assumption for the expected return on plan assets is primarily based on the determination of an expected return for its current portfolio. This determination is made using assumptions for return and volatility of the portfolio. Asset class assumptions are set using a combination of empirical and forward-looking analysis. To the extent historical results have been affected by unsustainable trends or events, the effects of those trends are quantified and removed. We apply a variety of models for filtering historical data and isolating the fundamental characteristics of asset classes. These models provide empirical return estimates for each asset class, which are then reviewed and combined with a qualitative assessment of long term relationships between asset classes before a return estimate is finalized. The qualitative analysis is intended to provide an additional means for addressing the effect of unrealistic or unsustainable short-term valuations or trends, resulting in return levels and behavior we believe are more likely to prevail over long periods. Effective in 2022, we changed the expected return on plan assets of the U.S. pension plans from 5.80% to 7.40% due to modifications to the investment strategy in order to reflect expected return assumptions based on recent capital market movements. The accumulated benefit obligation for all U.S. and foreign defined benefit pension plans was $356.3 million and $474.1 million for 2022 and 2021, respectively. All of the pension plans had accumulated benefit obligations in excess of their respective plan assets as of December 31, 2022 and 2021, with the exception of one foreign plan that had plan assets of $0.8 million and $2.0 million in excess of the accumulated benefit obligation as of December 31, 2022 and 2021, respectively. Our investment objective is to achieve an enhanced long-term rate of return on plan assets, subject to a prudent level of portfolio risk, for the purpose of enhancing the availability of benefits for participants. These investments are primarily comprised of equity and fixed income mutual funds. Our other investments are largely comprised of a hedge fund of funds and a structured credit fund. The equity funds are diversified in terms of domestic and international equity securities, as well as small, middle and large capitalization stocks. Our target allocation percentage is as follows: equity securities (26%) and fixed-income securities (74%). Equity funds are held for their expected return over inflation. Fixed-income funds are held for diversification relative to equities and as a partial hedge of interest rate risk with respect to plan liabilities. The other investments are held to further diversify assets within the plans and are designed to provide a mix of equity and bond like return with a bond like risk profile. The plans may also hold cash to meet liquidity requirements. Actual performance may not be consistent with the respective investment strategies. Investment risks and returns are measured and monitored on an ongoing basis through annual liability measurements and investment portfolio reviews to determine whether the asset allocation targets continue to represent an appropriate balance of expected risk and reward. The following table provides the fair values of the pension plan assets at December 31, 2022 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 769 $ 769 — — Money market funds 13 13 — — Equity securities: Managed volatility (b) 46,721 46,721 — — U.S. small/mid-cap equity (c) 6,054 6,054 — — World equity (excluding U.S.) (d) 28,159 28,159 — — Fixed income securities: Intermediate duration fund (e) 105,865 105,865 — — Long duration bond fund (f) 87,018 87,018 — — Corporate bond fund (g) 6,092 6,092 — — Emerging markets debt fund (h) 6,284 6,284 — — Corporate, government and foreign bonds 58,572 — $ 58,572 — Absolute return credit fund (i) 427 — 427 — Asset backed – home loans 153 — 153 — Other types of investments: Structured credit (j) 29 29 — Contract with insurance company (k) 11,114 — — $ 11,114 Total investments at fair value $ 357,270 $ 287,004 $ 59,152 $ 11,114 Total $ 357,270 The following table provides the fair values of the pension plan assets at December 31, 2021 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 923 $ 923 — — Money market funds 6 6 — — Equity securities: Managed volatility (b) 57,252 57,252 — — U.S. small/mid-cap equity (c) 7,532 7,532 — — World equity (excluding U.S.) (d) 34,287 34,287 — — Fixed income securities: Intermediate duration fund (e) 101,363 101,363 — — Long duration bond fund (f) 171,919 171,919 — — Corporate bond fund (g) 7,607 7,607 — — Emerging markets debt fund (h) 7,605 7,605 — — Corporate, government and foreign bonds 50,599 50,599 — — Absolute return credit fund (i) 671 — $ 671 — Asset backed – home loans 208 — 208 — Other types of investments: Contract with insurance company (k) 19,130 — — $ 19,130 Other 3 — — 3 Total investments at fair value $ 459,105 $ 439,093 $ 879 $ 19,133 Investments measured at Net asset value (l) 10,688 Total $ 469,793 (a) Information on asset categories described in notes (b)-(l) is derived from prospectuses and other material provided by the respective funds comprising the respective asset categories. (b) This category comprises mutual funds that invest in securities of U.S. and non-U.S. companies of all capitalization ranges that exhibit relatively low volatility. (c) This category comprises a mutual fund that invests at least 80% of its net assets in equity securities of small and mid-sized companies. The fund invests in common stocks or exchange traded funds holding common stock of U.S. companies with market capitalizations in the range of companies in the Russell 2500 Index. (d) This category comprises a mutual fund that invests at least 80% of its net assets in equity securities of foreign companies. These securities may include common stocks, preferred stocks, warrants, exchange traded funds based on an international equity index, derivative instruments whose value is based on an international equity index and derivative instruments whose value is based on an underlying equity security or a basket of equity securities. The fund invests in securities of foreign issuers located in developed and emerging market countries. However, the fund will not invest more than 35% of its assets in the common stocks or other equity securities of issuers located in emerging market countries. (e) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including U.S. and foreign corporate obligations, fixed income securities issued by sovereigns or agencies in both developed and emerging foreign markets, debt obligations issued by governments or other municipalities, and securities issued or guaranteed by the U.S. Government and its agencies. The fund will seek to maintain an effective average duration between three (f) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including securities issued or guaranteed by the U.S. Government and its agencies and instrumentalities, corporate bonds, asset-backed securities, exchange traded funds, mortgage-backed securities and collateralized mortgage-backed securities. The fund invests primarily in long duration government and corporate fixed income securities, and uses derivative instruments, including interest rate swap agreements and Treasury futures contracts, for the purpose of managing the overall duration and yield curve exposure of the Fund’s portfolio of fixed income securities. (g) This category comprises funds that invest primarily in higher-yielding fixed income securities, including corporate bonds and debentures, convertible and preferred securities and zero coupon obligations. (h) This category comprises a mutual fund that invests at least 80% of its net assets in fixed income securities of emerging market issuers, primarily in U.S. dollar-denominated debt of foreign governments, government-related and corporate issuers in emerging market countries and entities organized to restructure the debt of those issuers. (i) This category comprises a mutual fund that invests primarily in investment grade bonds and similar fixed income and floating rate securities. (j) This category comprises a fund that invests primarily in collateralized debt obligations and other structured credit vehicles and may include fixed income securities, loan participations, credit-linked notes, medium-term notes, pooled investment vehicles and derivative instruments. (k) This category comprises the asset established out of an agreement to purchase a bulk-annuity policy from an insurer to fully cover the liabilities for members of the pension plan. The asset value is based on the fair value of the contract as determined by the insurance company using inputs that are not observable. (l) This category comprises pooled institutional investments, primarily collective investment trusts. These funds are not listed on an exchange or traded in an active market and these investments are valued using their net asset value, which is generally based on the underlying asset values of the pooled investments held in the trusts. This category comprises the following funds: • a fund that invests primarily in collateralized debt obligations and other structured credit vehicles and may include fixed income securities, loan participations, credit-linked notes, medium-term notes, pooled investment vehicles and derivative instruments. • a hedge fund that invests in various other hedge funds. • funds that invest in underlying funds that acquire, manage, and dispose of real estate properties, with a focus on properties in the U.S. and the UK markets. Our contributions to U.S. and foreign pension plans during 2023 are expected to be approximately $1.4 million. Contributions to postretirement healthcare plans during 2023 are expected to be approximately $2.2 million. The following table provides information about the expected benefit payments under its U.S. and foreign plans for each of the five succeeding years and the aggregate of the five years thereafter, net of the annual average Medicare Part D subsidy of approximately $0.1 million: Pension Other Benefits 2023 $ 23,081 $ 2,174 2024 23,445 2,014 2025 23,934 1,986 2026 24,564 1,783 2027 24,940 1,576 Years 2028 — 2032 127,978 6,509 We maintain a number of defined contribution savings plans covering eligible U.S. and non-U.S. employees. We partially match employee contributions. Costs related to these plans were $24.3 million, $23.2 million and $21.7 million for 2022, 2021 and 2020, respectively.

Commitments and contingent liab

Commitments and contingent liabilities	12 Months Ended
Commitments and contingent liabilities	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Commitments and contingent liabilities Environmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. The nature of these activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At December 31, 2022 and 2021, we have recorded $2.5 million and $2.0 million, respectively, in accrued liabilities other liabilities Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment, environmental and other matters. As of December 31, 2022 and 2021, we have recorded accrued liabilities of $0.5 million and $0.2 million, respectively, in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. In August 2022, the U.S. Department of Justice through the United States Attorney’s Office for the Northern District of Georgia (collectively, the “DOJ”) closed the Civil Investigative Demand (a “CID”) of one of our subsidiaries, NeoTract, Inc., under the civil False Claims Act, 31 U.S.C. §3729. The CID, which began in 2020, related to the DOJ’s investigation of a single NeoTract customer and certain rebate programs offered to that customer in addition to communications and activities occurring both prior to our acquisition of NeoTract in October 2017 and thereafter. As part of the investigation the DOJ also opened an investigation into NeoTract’s operations broadly. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Other: We have been subject to an investigation by Chinese authorities related to a technical error regarding our country of origin designation for certain products we imported into China. Had the error not been made, we would have been obligated to make increased tariff payments in late 2018 through the first quarter of 2021. In addition to the tariffs and related interest, the Chinese authorities may impose a penalty for the unpaid tariffs. To date, we have remitted payment for the requested amounts of the increased tariffs, and we believe this to be the final action required to close the case. However, we have not received confirmation from the Chinese authorities that the case is closed and as a result, it remains possible that they may request payment for penalties and interest in the future. We believe the range of penalties could be between 30% and 200% of the increased tariff amount or between $3 million and $20 million. In 2015, the Italian parliament enacted legislation that, among other things, imposed a “payback” measure on medical device companies that supply goods and services to the Italian National Healthcare System. Under the measure, companies are required to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. The payment amounts are calculated based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty exists related to the enforceability of and implementation process for the payback law. In response to decrees issued by the Italian Ministry of Health, the various Italian regions issued invoices to medical device companies, including Teleflex, under the payback measure in the fourth quarter of 2022 seeking payment with respect to excess expenditures for the years 2015 through 2018. Following the issuance of the invoices, we and numerous other medical device companies filed appeals with the Italian administrative courts challenging the enforceability of the payback measure, which appeals remain pending. As of December 31, 2022, our reserve for this matter is $10.9 million, $2.6 million of which was recorded as a reduction of revenue for 2022. If the payback was to ultimately be enforced in its existing form, we estimate that we would be required to remit payments in excess of our current reserve of up to $23.0 million.

Business segments and other inf

Business segments and other information	12 Months Ended
Business segments and other information	Dec. 31, 2022
Segment Reporting [Abstract]
Business segments and other information	Business segments and other information An operating segment is a component (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. We do not evaluate our operating segments using discrete asset information. We have four reportable segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM (Original Equipment Manufacturer and Development Services). Our reportable segments, other than the OEM segment, design, manufacture and distribute medical devices primarily used in critical care and surgical applications and generally serve two end-markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The following tables present our segment results for the years ended December 31, 2022, 2021 and 2020: Year Ended December 31, 2022 2021 2020 Americas $ 1,653,724 $ 1,659,309 $ 1,465,035 EMEA 558,373 606,807 584,859 Asia 306,320 297,766 267,016 OEM 272,624 245,681 220,246 Net revenues $ 2,791,041 $ 2,809,563 $ 2,537,156 Year Ended December 31, 2022 2021 2020 Americas $ 452,030 $ 424,225 $ 401,391 EMEA 42,465 94,865 81,348 Asia 82,786 84,648 51,238 OEM 65,379 56,210 44,852 Total segment operating profit (1) 642,660 659,948 578,829 Unallocated expenses (2) (142,935) (31,853) (155,761) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 499,725 $ 628,095 $ 423,068 (1 ) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Commencing on January 1, 2022, all corporate expenses are allocated amongst the segments in proportion to the respective amounts of net revenues. The change in the measure of segment operating profit does not impact period over period comparability because the change was immaterial. For the year ended December 31, 2021, corporate expenses were allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring and impairment charges and gain on sale of business. Year Ended December 31, 2022 2021 2020 Americas $ 162,898 $ 164,102 $ 151,111 EMEA 39,957 45,022 47,012 Asia 10,107 11,140 13,594 OEM 17,628 17,098 15,535 Consolidated depreciation and amortization $ 230,590 $ 237,362 $ 227,252 Geographic data The following tables provide total net revenues and total net property, plant and equipment by geographic region for the years ended December 31, 2022, 2021 and 2020 and as of December 31, 2022 and 2021, respectively. Year Ended December 31, 2022 2021 2020 Net revenues (based on selling location): U.S. $ 1,786,467 $ 1,769,488 $ 1,567,144 Europe 622,343 665,000 646,577 Asia Pacific 270,749 263,022 230,267 All other 111,482 112,053 93,168 $ 2,791,041 $ 2,809,563 $ 2,537,156 As of December 31, Net property, plant and equipment: 2022 2021 U.S. $ 193,618 $ 206,876 Malaysia 73,441 72,541 Mexico 82,334 69,471 All other 97,812 94,870 $ 447,205 $ 443,758

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	Dec. 31, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS (Dollars in thousands) ALLOWANCE FOR DOUBTFUL ACCOUNTS Balance at Beginning of Year (Reversals) additions Accounts Receivable Write-offs Translation and Other Balance at End of Year December 31, 2022 $ 10,799 $ (786) $ (1,750) $ 299 $ 8,562 December 31, 2021 $ 12,875 $ 1,542 $ (3,001) $ (617) $ 10,799 December 31, 2020 $ 9,055 $ 3,798 $ (1,336) $ 1,358 $ 12,875 DEFERRED TAX ASSET VALUATION ALLOWANCE Balance at Beginning of Year Additions Charged to Expense Reductions Credited to Expense Translation and Other Balance at End of Year December 31, 2022 $ 143,177 $ 8,489 $ (59,520) $ (615) $ 91,531 December 31, 2021 $ 155,008 $ 7,770 $ (15,384) $ (4,217) $ 143,177 December 31, 2020 $ 119,233 $ 30,640 $ (59) $ 5,194 $ 155,008

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
Summary of significant accounting policies (Policies)	Dec. 31, 2022
Accounting Policies [Abstract]
Consolidation	Consolidation: The consolidated financial statements include the accounts of Teleflex Incorporated and its subsidiaries (referred to herein as “we,” “us,” “our” and “Teleflex"). Intercompany transactions are eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and reflect management’s estimates and assumptions that affect the recorded amounts.
Use of estimates	Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents: All highly liquid debt instruments with an original maturity of three months or less are classified as cash equivalents. The carrying value of cash equivalents approximates the current market value.
Accounts receivable	Accounts receivable: Accounts receivable represent amounts due from customers related to the sale of products and provision of services. Our allowance for credit losses is maintained for trade accounts receivable based on the expected collectability of accounts receivable and losses expected to be incurred over the life of our receivables. Considerations to determine credit losses include our historical collection experience, the length of time an account is outstanding, the financial position of the customer, information provided by credit rating services, as well as the consideration of events or circumstances indicating historic collection rates may not be indicative of future collectability.
Inventories	Inventories: Inventories are valued at the lower of cost or net realizable value. The cost of our inventories is determined using the average cost method. Elements of cost in inventory include raw materials, direct labor, and manufacturing overhead. In estimating net realizable value, we evaluate inventory for excess and obsolete quantities based on estimated usage and sales, among other factors.
Property, plant and equipment	Property, plant and equipment: Property, plant and equipment are stated at cost, net of accumulated depreciation. Costs incurred to develop internal-use computer software during the application development stage generally are capitalized. Costs of enhancements to internal-use computer software are capitalized, provided that these enhancements result in additional functionality. Other additions and those improvements which increase the capacity or lengthen the useful lives of the assets are also capitalized. Composite useful lives for categories of property, plant and equipment, which are depreciated on a straight-line basis, are as follows: buildings — 30 years; machinery and equipment — 3 to 15 years; computer equipment and software — 3 to 10 years. Leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the remaining lease term. Repairs and maintenance costs are expensed as incurred.
Goodwill and other intangible assets	Goodwill and other intangible assets: Goodwill and other indefinite-lived intangible assets are not amortized but are tested for impairment annually during the fourth quarter or more frequently if events or changes in circumstances indicate that an impairment may exist. Impairment losses, if any, are included in income from operations. The goodwill impairment test is applied to each of our reporting units. For purposes of this assessment, a reporting unit is an operating segment, or a business one level below an operating segment (also known as a component) if discrete financial information is prepared for that business and regularly reviewed by segment management. However, separate components are aggregated as a single reporting unit if they have similar economic characteristics. In performing the goodwill impairment test, we may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors may include, but are not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for our products and services, regulatory and political developments, and entity specific factors such as strategies and financial performance. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying value, we proceed to a quantitative impairment test, described below. Alternatively, we may elect to bypass the qualitative assessment and perform the quantitative impairment test. Under a quantitative impairment test, we compare the fair value of a reporting unit to its carrying value. If the reporting unit fair value exceeds the carrying value, there is no impairment. If the reporting unit carrying value exceeds the fair value, we recognize an impairment loss based on the amount the carrying value of the reporting unit exceeds its fair value. We did not record a goodwill impairment charge for the year ended December 31, 2022. Our intangible assets consist of customer relationships, intellectual property, distribution rights, in-process research and development ("IPR&D"), trade names and non-competition agreements. We define IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and is required be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or upon abandonment. Upon completion of the development project (generally when regulatory approval to market the product that utilizes the technology is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off. We test our indefinite-lived intangible assets for impairment annually, or more frequently if events or changes in circumstances indicate that an impairment may have occurred. Similar to the goodwill impairment test process, we may elect to perform a qualitative assessment. If, after completing the qualitative assessment, we determine it is more likely than not that the fair value of the indefinite-lived intangible asset is greater than its carrying amount, the asset is not impaired. If we conclude it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, we then proceed to a quantitative impairment test, which consists of a comparison of the fair value of the intangible asset to its carrying amount. Intangible assets that do not have indefinite lives, consisting of intellectual property, customer relationships, distribution rights, certain trade names and non-competition agreements, are amortized over their estimated useful lives, which are as follows: intellectual property, 5 to 20 years; customer relationships, 8 to 27 years; distribution rights, 10 years; trade names, 10 to 30 years; non-compete agreement, 6 years. The weighted average remaining amortization period with respect to our intangible assets is approximately 15 years. We periodically evaluate the reasonableness of the useful lives of these assets.
Long-lived assets	Long-lived assets: We assess the remaining useful life and recoverability of long-lived assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The assessment is based on various analyses, including undiscounted cash flow and profitability projections that incorporate, as applicable, the impact of the asset on the existing business. Therefore, the evaluation involves significant management judgment. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.
Foreign currency translation	Foreign currency translation: Assets and liabilities of subsidiaries with non-United States dollar denominated functional currencies are translated into United States dollars at the rates of exchange at the balance sheet date; income and expenses are translated at the average rates of exchange prevailing during the year. The translation adjustments are reported as a component of accumulated other comprehensive loss.
Derivative financial instruments	Derivative financial instruments: We use derivative financial instruments primarily for purposes of hedging exposures to fluctuations in foreign currency exchange rates. All instruments are entered into for other than trading purposes. All derivatives are recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recorded in the consolidated statement of comprehensive income as other comprehensive income (loss), if the instrument is designated as part of a hedge transaction. Gains or losses on derivative instruments reported in other comprehensive income (loss) are reclassified to the consolidated statement of income in the period in which earnings are affected by the underlying hedged item. Gains or losses on derivative instruments representing hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, if any, are recognized in the consolidated statement of income for the period in which such gains and losses occur. If the hedging relationship ceases to be highly effective or it becomes probable that an expected transaction will no longer occur, gains or losses on the derivative instrument are recorded in the consolidated statement of income for the period in which either such event occurs. For non-designated derivatives, gains and losses are reported as selling, general and administrative expenses in the consolidated statement of income. Cash flows from derivatives are recognized in the consolidated statements of cash flows in a manner consistent with the recognition of the underlying transactions.
Share-based compensation	Share-based compensation: We estimate the fair value of share-based awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest, which is derived, in
Income taxes	Income taxes: The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, and to reflect operating loss and tax credit carryforwards. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Provision has been made for income taxes on unremitted earnings of subsidiaries and affiliates, except to the extent that such earnings are deemed to be permanently reinvested. Significant judgment is required in determining income tax provisions and in evaluating tax positions. We establish additional provisions for income taxes when, despite the belief that tax positions are supportable, there remain certain positions that do not meet the minimum probability threshold, which is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority. In the normal course of business, we are examined by various federal, state and non-U.S. tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of our provision for income taxes. Interest accrued with respect to unrecognized tax benefits and income tax related penalties are both included in taxes on income from continuing operations. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability and deferred taxes in the period in which the facts that give rise to an adjustment become known.
Pensions and other postretirement benefits	Pensions and other postretirement benefits: We provide a range of benefits to eligible employees and retired employees, including benefits available pursuant to pension and postretirement healthcare benefits plans. We record annual amounts relating to these plans based on calculations which include various actuarial assumptions such as discount rates, expected rates of return on plan assets, compensation increases, turnover rates and healthcare cost trend rates. We review our actuarial assumptions on an annual basis and make modifications to the assumptions based on current rates and trends when appropriate. The effect of the modifications is generally amortized over future periods.
Restructuring costs	Restructuring costs: We primarily recognize employee termination benefits when payment becomes probable and reasonably estimable because they are provided under an ongoing benefit arrangement and are based on existing plans, historical experience and negotiated settlements of prior plans. Termination benefits provided under one-time termination benefits arrangements, if any, are recognized upon communication to the employee. We recognize charges ratably over the future service period if the employee is required to render service until termination. Other restructuring costs may include facility closure, employee relocation, equipment relocation and outplacement costs and are recognized in the period they are incurred.
Contingent consideration related to business acquisitions	Contingent consideration related to business acquisitions: In connection with business acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified objectives such as receipt of regulatory approval, commercialization of a product or achievement of sales targets. In a business combination, we record a contingent liability, as of the acquisition date, representing the estimated fair value of the contingent consideration that we expect to pay. We remeasure the fair value of our contingent consideration arrangements each reporting period and, based on new developments, record changes in fair value until either the contingent consideration obligation is satisfied through payment upon the achievement of, or the obligation no longer exists due to the failure to achieve, the specified objectives. The change in the fair value is recorded in selling, general and administrative expenses in the consolidated statement of income. A contingent consideration payment is classified as a financing activity in the consolidated statement of cash flows to the extent it was recorded as a liability as of the acquisition date. Any additional amount paid in excess of the amount initially accrued is classified as an operating activity in the consolidated statement of cash flows.
Revenue recognition	Revenue recognition: We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For the OEM segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which represented 88%, 10% and 2% of our consolidated net revenues, respectively, for the year ended December 31, 2022. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. We have made the following revenue accounting policy elections and elected to use certain practical expedients: (1) we account for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) we do not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, we expect the period between the time when we transfer a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) we expense costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) we account for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) we classify shipping and handling costs within cost of goods sold; and (6) with respect to the OEM segment, we have applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less. The amount of consideration we receive and revenue we recognize varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. Our policy is to accept returns only in cases in which the product is defective and covered under our standard warranty provisions. When we give customers the right to return products, we estimate the expected returns based on an analysis of historical experience. The liability for returns and allowances was $17.9 million and $15.2 million as of December 31, 2022 and 2021, respectively. In estimating customer rebates, we consider the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers (as we have a history of providing similar rebates on similar products to similar customers) and other relevant information. The reserve for customer incentive programs, including customer rebates, was $29.0 million and $26.4 million at December 31, 2022 and 2021, respectively. We expect the amounts subject to the reserve as of December 31, 2022 to be paid within 90 days subsequent to period-end.
Leases	Leases: We have made an accounting policy election not to apply the lease accounting recognition provisions to short term leases (leases with a lease term of 12 months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, we will recognize the lease payments for short term leases on a straight-line basis over the lease term. We have made an accounting policy election to not separate lease and non-lease components and instead will account for each separate lease component and the non-lease components associated with that lease component as a single lease component.
Recently issued accounting standards	Recently issued accounting standards From time to time, new accounting guidance issued by the FASB or other standard setting bodies is adopted as of the specified effective date or, when permitted by the guidance and as determined by us, as of an earlier date. We have assessed recently issued guidance that is not yet effective and believe the new guidance that we have assessed will not have a material impact on our results of operations, cash flows or financial position.

Net revenues (Tables)

Net revenues (Tables)	12 Months Ended
Net revenues (Tables)	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table disaggregates revenue by global product category for the year ended December 31, 2022, 2021 and 2020. Year Ended December 31, 2022 2021 2020 Vascular access $ 683,612 $ 700,240 $ 657,703 Anesthesia 388,890 380,140 302,293 Interventional 445,018 427,500 382,435 Surgical 392,917 377,756 317,200 Interventional urology 322,832 341,661 290,022 OEM 272,624 245,681 220,246 Other (1) 285,148 336,585 367,257 Net revenues (2) $ 2,791,041 $ 2,809,563 $ 2,537,156 (1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products). Certain product lines within the respiratory product category were sold during 2021. See Note 4 for additional information related to the Respiratory business divestiture. (2) The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments includes net revenues from each of the non-OEM product categories listed above.

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	12 Months Ended
Acquisitions and Divestitures (Tables)	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the fair value of the assets acquired and liabilities assumed with respect to the Standard Bariatrics acquisition: (Dollars in thousands) Assets Current assets $ 8,028 Property, plant and equipment 3,342 Intangible assets 154,450 Goodwill 71,420 Other assets 2,122 Total assets acquired 239,362 Less: Current liabilities 2,661 Other liabilities 24,896 Liabilities assumed 27,557 Net assets acquired $ 211,805
Schedule of Identifiable Intangible Assets Acquired and Ranges of Useful Lives	The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of the Standard Bariatrics acquisition: Standard Bariatrics Fair value Useful life (years) Intellectual property $ 128,300 15 Trade names 22,500 25 Customer relationships 3,650 11
Schedule of Business Acquisitions, by Acquisition	Year Ended December 31, 2022 2021 2020 Non cash investing and financing activities of continuing operations: Acquisition of businesses $ 43,168 $ — $ —

Restructuring and impairment _2

Restructuring and impairment charges (Tables)	12 Months Ended
Restructuring and impairment charges (Tables)	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Summary of Current Cost Estimates by Major Type of Cost	The following table provides a summary of the cost estimates by major type of expense associated with the 2022 restructuring plan: Total estimated amount expected to be incurred Plan expense estimates: (Dollars in millions) Termination benefits $18 million to $22 million Other costs (1) $1 million to $1 million Restructuring Charges $19 million to $23 million Restructuring related charges (2) $20 million to $25 million Total restructuring and restructuring related charges $39 million to $48 million (1) Includes facility closure and outplacement costs. (2) Restructuring related charges represent costs that are directly related to the program and principally comprise costs to transfer manufacturing operations to the existing lower-cost locations, project management costs and accelerated depreciation. The plan also includes an $8.1 million non cash tax related charge arising from establishing a valuation allowance against a local deferred tax asset, which is no longer expected to be utilized as a result of the transfer. Excluding this tax charge, the majority of the restructuring related charges are expected to be recognized within cost of goods sold. Total estimated amount expected to be incurred Plan expense estimates: (Dollars in millions) Restructuring charges (1) $5 million to $8 million Restructuring related charges (2) $19 million to $22 million Total restructuring and restructuring related charges $24 million to $30 million (1) Substantially all of the charges consist of employee termination benefit costs. (2) Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold.
Schedule of Restructuring Reserve	The following table summarizes the restructuring reserve activity related to our 2022 restructuring plan, Respiratory divestiture plan as well as the 2019 and 2018 Footprint realignment plans: 2022 restructuring plan Respiratory divestiture plan 2019 Footprint realignment plan 2018 Footprint realignment plan Balance at December 31, 2020 (1) $ — $ — $ 8,054 $ 50,081 Subsequent accruals — 2,694 253 2,476 Cash payments — (7) (4,982) (4,813) Foreign currency translation and other — (86) (19) (3,679) Balance at December 31, 2021 (1) — 2,601 3,306 44,065 Subsequent accruals 15,523 578 (987) 2,076 Cash payments (978) (149) (874) (24,310) Foreign currency translation and other 315 19 — (3,292) Balance at December 31, 2022 (1) $ 14,860 $ 3,049 $ 1,445 $ 18,539 (1) The restructuring reserves as of December 31, 2022, 2021 and 2020 consisted mainly of accruals related to termination benefits. Other costs (facility closure, employee relocation, equipment relocation and outplacement costs) were expensed and paid in the same period.
Restructuring and Other Impairment Charges	The restructuring and impairment charges recognized for the years ended December 31, 2022, 2021, and 2020 consisted of the following: 2022 Termination benefits Other Costs (1) Total 2022 Restructuring plan $ 15,465 $ 58 $ 15,523 Respiratory divestiture plan 504 74 578 2019 Footprint realignment plan (1,120) 133 (987) 2018 Footprint realignment plan 1,230 846 2,076 Other restructuring programs (2) 1,306 306 1,612 Total restructuring charges 17,385 1,417 18,802 Asset impairment charges — 1,497 1,497 Total restructuring and impairment charges $ 17,385 $ 2,914 $ 20,299 2021 Termination benefits Other Costs (1) Total Respiratory divestiture plan $ 2,687 $ 7 $ 2,694 2021 Restructuring plan 7,280 77 7,357 2019 Footprint realignment plan (111) 364 253 2018 Footprint realignment plan 2,335 141 2,476 Other restructuring programs (3) (429) 2,648 2,219 Total restructuring charges 11,762 3,237 14,999 Asset impairment charges — 6,739 6,739 Total restructuring and impairment charges $ 11,762 $ 9,976 $ 21,738 2020 Termination benefits Other Costs (1) Total 2020 Workforce reduction plan $ 8,494 $ 353 $ 8,847 2019 Footprint realignment plan 647 895 1,542 2018 Footprint realignment plan 5,565 383 5,948 Other restructuring programs (4) (72) 838 766 Total restructuring charges 14,634 2,469 17,103 Asset impairment charges — 21,388 21,388 Total restructuring and impairment charges $ 14,634 $ 23,857 $ 38,491 (1) Includes facility closure, contract termination and other exit costs. (2) Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities, the 2014 Footprint realignment plan and the 2020 Workforce reduction plan, a program initiated in the second quarter of 2020. (3) Includes the 2020 Workforce reduction plan and the 2014 Footprint realignment plan. (4) Includes activity primarily related to the 2016 and 2014 Footprint realignment plans.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories at December 31, 2022 and 2021 consist of the following: 2022 2021 Raw materials $ 186,641 $ 146,433 Work-in-process 98,993 81,503 Finished goods 292,873 249,707 Inventories $ 578,507 $ 477,643

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
Property, plant and equipment (Tables)	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Major Classes of Property, Plant and Equipment at Cost	The major classes of property, plant and equipment, at cost, at December 31, 2022 and 2021 were as follows: 2022 2021 Land, buildings and leasehold improvements $ 272,578 $ 285,305 Machinery and equipment 462,447 475,040 Computer equipment and software 192,785 191,605 Construction in progress 76,077 49,782 1,003,887 1,001,732 Less: Accumulated depreciation (556,682) (557,974) Property, plant and equipment, net $ 447,205 $ 443,758

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	12 Months Ended
Goodwill and other intangible assets (Tables)	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill, by Reporting Segment	Changes in the carrying amount of goodwill, by reportable operating segment, for the years ended December 31, 2022 and 2021 were as follows: Americas EMEA Asia OEM Total Balance as of December 31, 2020 Goodwill $ 2,032,410 $ 536,228 $ 237,446 $ 112,010 $ 2,918,094 Accumulated impairment losses (332,128) — — — (332,128) 1,700,282 536,228 237,446 112,010 2,585,966 Goodwill disposed (21,802) (7,537) (6,406) — (35,745) Goodwill related to acquisitions (1,560) (232) (163) — (1,955) Translation and other adjustments (696) (36,310) (7,058) — (44,064) Balance as of December 31, 2021 1,676,224 492,149 223,819 112,010 2,504,202 Goodwill related to acquisitions 53,970 7,281 10,169 — 71,420 Translation and other adjustments 899 (30,906) (8,885) — (38,892) Balance as of December 31, 2022 $ 1,731,093 $ 468,524 $ 225,103 $ 112,010 $ 2,536,730
Components of Intangible Assets	Intangible assets at December 31, 2022 and 2021 consisted of the following: Gross Carrying Amount Accumulated Amortization 2022 2021 2022 2021 Customer relationships $ 1,328,539 $ 1,328,611 $ (497,335) $ (441,059) In-process research and development 27,075 28,158 — — Intellectual property 1,599,355 1,440,643 (646,643) (560,740) Distribution rights 23,115 23,434 (21,090) (20,630) Trade names 564,023 549,269 (71,128) (59,249) Non-compete agreements 21,429 22,783 (21,175) (22,153) $ 3,563,536 $ 3,392,898 $ (1,257,371) $ (1,103,831)
Estimated Annual Amortization Expense	Amortization expense related to intangible assets was $164.1 million, $165.6 million, and $158.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. The estimated annual amortization expense for each of the five succeeding years is as follows: 2023 $ 167,100 2024 165,000 2025 164,100 2026 161,300 2027 158,100

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2022
Leases [Abstract]
Schedule of Lessee, Operating Lease, Liability, Maturity	Maturities of lease liabilities December 31, 2022 2023 $ 24,613 2024 21,483 2025 19,884 2026 19,206 2027 18,338 2028 and thereafter 63,242 Total lease payments 166,766 Less: interest (26,872) Present value of lease liabilities $ 139,894
Supplemental Information, Lessee, Operating Lease	Supplemental information December 31, 2022 December 31, 2021 Total lease liabilities (1) $ 139,894 $ 138,163 Cash paid for amounts included in the measurement of lease liabilities within operating cash flows $ 28,308 $ 29,199 Right of use assets obtained in exchange for operating lease obligations $ 25,202 $ 55,290 Weighted average remaining lease term 7.9 years 7.9 years Weighted average discount rate 4.2 % 3.7 % (1) The current portion of the operating lease liability is included in other current liabilities .

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
Borrowings (Tables)	Dec. 31, 2022
Debt Disclosure [Abstract]
Components of Long-Term Debt	Our borrowings at December 31, 2022 and 2021 were as follows: 2022 2021 Senior Credit Facility: Revolving credit facility, at a rate of 5.80% at December 31, 2022, and 1.48% at December 31, 2021, due 2027 $ 148,250 $ 141,000 Term loan facility, at a rate of 5.80% at December 31, 2022 and 1.48% at December 31 2021, due 2027 500,000 647,500 4.625% Senior Notes due 2027 500,000 500,000 4.25% Senior Notes due 2028 500,000 500,000 Securitization program, at a rate of 5.11% at December 31, 2022 and 1.00% at December 31, 2021 75,000 75,000 1,723,250 1,863,500 Less: Unamortized debt issuance costs (11,727) (13,398) 1,711,523 1,850,102 Current portion of borrowings (87,500) (110,000) Long-term borrowings $ 1,624,023 $ 1,740,102
Fair Value of Debt	The following table provides the fair value of our debt as of December 31, 2022 and 2021, which is valued based on Level 2 inputs within the hierarchy used to measure fair value (see Note 12 to the consolidated financial statements for further information): December 31, 2022 December 31, 2021 Fair value of debt $ 1,674,232 $ 1,893,518
Aggregate Amounts of Long-Term Debt	Debt Maturities As of December 31, 2022, the aggregate amounts of long-term debt, demand loans and debt under our securitization program that will mature during each of the next four years and thereafter were as follows: 2023 $ 87,500 2024 12,500 2025 25,000 2026 25,000 2027 and thereafter 1,573,250
Schedule of Cash Flow, Supplemental Disclosures, Debt	Supplemental cash flow information Year Ended December 31, 2022 2021 2020 Cash interest paid $ 70,918 $ 73,598 $ 79,533

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
Financial instruments (Tables)	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The following table presents the locations in the consolidated balance sheets and fair value of derivative instruments as of December 31, 2022 and 2021: December 31, 2022 December 31, 2021 Asset derivatives: Designated foreign currency forward contracts $ 3,154 $ 1,957 Non-designated foreign currency forward contracts 41 56 Cross-currency interest rate swap 48,503 21,718 Prepaid expenses and other current assets 51,698 23,731 Cross-currency interest rate swap 11,912 9,560 Other assets 11,912 9,560 Total asset derivatives $ 63,610 $ 33,291 Liability derivatives: Designated foreign currency forward contracts $ 983 $ 993 Non-designated foreign currency forward contracts 477 147 Other current liabilities 1,460 1,140 Total liability derivatives $ 1,460 $ 1,140
Schedule of foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense	The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the year ended December 31, 2022 and December 31, 2021: December 31, 2022 December 31, 2021 Foreign exchange gains $ 22,399 $ 34,849 Interest benefit 20,880 19,296

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
Fair value measurement (Tables)	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 and 2021: Basis of fair value measurement December 31, 2022 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 10,097 $ 10,097 $ — $ — Derivative assets 63,610 — 63,610 — Derivative liabilities 1,460 — 1,460 — Contingent consideration liabilities 44,022 — — 44,022 Basis of fair value measurement December 31, 2021 (Level 1) (Level 2) (Level 3) Investments in marketable securities $ 19,186 $ 19,186 $ — $ — Derivative assets 33,291 — 33,291 — Derivative liabilities 1,140 — 1,140 — Contingent consideration liabilities 9,814 — — 9,814 There were no transfers of financial assets or liabilities into or out of Level 3 within the fair value hierarchy during the years ended December 31, 2022 or 2021.
Schedule of Valuation Techniques	The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities. Contingent Consideration Liability Valuation Technique Unobservable Input Revenue-based Monte Carlo simulation Revenue volatility 31.8 % Risk free rate Cost of debt structure Projected year of payment 2024 - 2026
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes in our contingent consideration liabilities for the years ended December 31, 2022 and 2021: Contingent consideration 2022 2021 Beginning balance – January 1 $ 9,814 $ 36,633 Initial estimate upon acquisition 38,800 — Payments (6,975) (31,678) Revaluations and other adjustments 2,350 4,895 Translation adjustment 33 (36) Ending balance – December 31 $ 44,022 $ 9,814

Shareholders' equity (Tables)

Shareholders' equity (Tables)	12 Months Ended
Shareholders' equity (Tables)	Dec. 31, 2022
Equity [Abstract]
Schedule of Weighted Average Number of Shares	The following table provides a reconciliation of basic to diluted weighted average shares outstanding: 2022 2021 2020 Basic 46,898 46,774 46,488 Dilutive effect of share based awards 411 653 799 Diluted 47,309 47,427 47,287
Schedule of Accumulated Other Comprehensive Income (Loss)	The following tables provides information relating to the changes in accumulated other comprehensive income (loss), net of tax, for each of the years ended December 31, 2022 and 2021: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2020 $ (482) $ (150,257) $ (146,559) $ (297,298) Other comprehensive income (loss) before reclassifications 351 6,192 (63,191) (56,648) Amounts reclassified from accumulated other comprehensive income 1,212 5,775 — 6,987 Net current-year other comprehensive income (loss) 1,563 11,967 (63,191) (49,661) Balance at December 31, 2021 1,081 (138,290) (209,750) (346,959) Other comprehensive income (loss) before reclassifications 7,179 (2,606) (62,904) (58,331) Amounts reclassified from accumulated other comprehensive income (3,329) 5,097 — 1,768 Net current-year other comprehensive income (loss) 3,850 2,491 (62,904) (56,563) Balance at December 31, 2022 $ 4,931 $ (135,799) $ (272,654) $ (403,522)
Reclassification out of Accumulated Other Comprehensive Income	The following table provides information relating to the (gains) losses recognized in the statements of income including the reclassifications of losses (gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the years ended December 31, 2022, 2021 and 2020: Year Ended December 31, 2022 2021 2020 (Gains) losses on designated foreign exchange forward contracts: Cost of goods sold $ (3,532) $ 1,150 $ 2,354 Total before tax (3,532) 1,150 2,354 Taxes expense (benefit) 203 62 (240) Net of tax $ (3,329) $ 1,212 $ 2,114 Amortization of pension and other postretirement benefits items: Actuarial losses (1) $ 7,660 $ 8,543 $ 7,253 Prior-service credits (1) (1,017) (1,012) 33 Total before tax 6,643 7,531 7,286 Tax benefit (1,546) (1,756) (1,701) Net of tax $ 5,097 $ 5,775 $ 5,585 Impact on income from continuing operations, net of tax $ 1,768 $ 6,987 $ 7,699 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 16 for additional information).

Stock compensation plans (Table

Stock compensation plans (Tables)	12 Months Ended
Stock compensation plans (Tables)	Dec. 31, 2022
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Summary of Share-based Compensation Activity	The following table summarizes the share-based compensation activity: 2022 2021 2020 Share-based compensation expense $ 27,224 $ 22,937 $ 20,739 Total income tax benefit recognized for share-based compensation arrangements 6,824 10,912 21,958 Net excess tax benefit 1,292 6,355 17,549
Weighted-Average Assumptions used to Estimate Fair Value of Options Granted	The fair value of options granted in 2022, 2021 and 2020 was estimated at the date of grant using a Black-Scholes option pricing model. The following weighted-average assumptions were used: 2022 2021 2020 Risk-free interest rate 1.56 % 0.67 % 1.16 % Expected life of option 5.03 years 5.01 years 5.00 years Expected dividend yield 0.41 % 0.34 % 0.39 % Expected volatility 30.09 % 30.03 % 23.98 %
Summary of Stock Option Activity	The following table summarizes the option activity during 2022: Shares Subject to Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding, beginning of the year 1,107,999 $ 214.13 Granted 156,918 330.03 Exercised (27,518) 95.07 Forfeited or expired (8,551) 359.54 Outstanding, end of the year 1,228,848 230.58 4.77 $ 66,774 Exercisable, end of the year 990,842 $ 201.19 3.84 $ 66,746
Weighted-Average Assumptions used to Estimate Fair Value of Non-Vested Shares Granted	The following weighted-average assumptions were used: 2022 2021 2020 Risk-free interest rate 1.57 % 0.28 % 1.07 % Expected dividend yield 0.42 % 0.34 % 0.38 %
Summary of Non-Vested Restricted Stock Unit Activity	The following table summarizes the non-vested restricted stock unit activity during 2022: Number of Non-Vested Shares Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding, beginning of the year 135,378 $ 343.89 Granted 85,780 323.35 Vested (51,831) 290.75 Forfeited (21,359) 352.06 Outstanding, end of the year 147,968 $ 349.42 1.5 $ 36,970

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
Income taxes (Tables)	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Components of Provision for Income Taxes from Continuing Operations	The following table summarizes the components of the provision for income taxes from continuing operations: 2022 2021 2020 Current: Federal $ 32,798 $ 134,336 $ 11,148 State 8,747 16,970 9,644 Non-U.S. 56,442 35,399 35,042 Deferred: Federal (27,528) (85,272) (9,475) State 10,116 (16,933) (13,734) Non-U.S. 2,428 (10,151) (10,694) $ 83,003 $ 74,349 $ 21,931
Summaries of U.S. and Non-U.S. Components of Income from Continuing Operations Before Taxes	The following table summarizes the U.S. and non-U.S. components of income from continuing operations before taxes: 2022 2021 2020 U.S. $ 164,151 $ 209,231 $ 233,034 Non-U.S. 281,768 350,237 124,698 $ 445,919 $ 559,468 $ 357,732
Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate	Reconciliations between the statutory federal income tax rate and the effective income tax rate are as follows: 2022 2021 2020 Federal statutory rate 21.0 % 21.0 % 21.0 % Tax effect of international items (4.6) (6.0) (5.3) Foreign merger - deferred taxes — — — Excess tax benefits related to share-based compensation (0.3) (1.1) (4.9) State taxes, net of federal benefit 3.4 0.1 (0.3) Uncertain tax contingencies (0.4) (0.1) (0.5) Contingent consideration 0.1 0.2 (2.2) Intellectual property impairment charge — — (1.2) Research and development tax credit (1.0) (0.8) (1.1) Other, net 0.5 — 0.6 18.6 % 13.3 % 6.1 %
Deferred Tax Assets and Liabilities	The following table summarizes significant components of our deferred tax assets and liabilities at December 31, 2022 and 2021: 2022 2021 Deferred tax assets: Tax loss and credit carryforwards $ 110,857 $ 168,113 Lease Liabilities 32,339 32,127 Pension 1,163 350 Reserves and accruals 64,498 64,421 Other 24,013 4,379 Less: valuation allowances (91,531) (143,177) Total deferred tax assets 141,339 126,213 Deferred tax liabilities: Property, plant and equipment 25,427 24,479 Intangibles — stock acquisitions 379,298 352,139 Unremitted non-U.S. earnings 67,833 73,385 Lease Assets 32,339 32,127 Other 18,926 7,387 Total deferred tax liabilities 523,823 489,517 Net deferred tax liability $ (382,484) $ (363,304)
Uncertain Tax Positions for Liabilities Associated with Unrecognized Tax Benefits	Uncertain Tax Positions : The following table is a reconciliation of the beginning and ending balances for liabilities associated with unrecognized tax benefits for the years ended December 31, 2022, 2021 and 2020: 2022 2021 2020 Balance at January 1 $ 6,105 $ 7,230 $ 7,561 Increase in unrecognized tax benefits related to prior years 215 — 1,286 Decrease in unrecognized tax benefits related to prior years (761) — — Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations (1,117) (956) (1,864) (Decrease) increase in unrecognized tax benefits due to foreign currency translation (182) (169) 247 Balance at December 31 $ 4,260 $ 6,105 $ 7,230
Examinations by Major Tax Jurisdictions	The taxable years for which the applicable statute of limitations remains open by major tax jurisdictions are as follows: Beginning Ending U.S. 2019 2022 Canada 2018 2022 China 2017 2022 Czech Republic 2019 2022 France 2019 2022 Germany 2011 2022 India 2002 2022 Ireland 2018 2022 Italy 2017 2022 Malaysia 2015 2022 Singapore 2018 2022
Schedule of Cash Flow, Supplemental Disclosures, Income Tax	Supplemental cash flow information Year Ended December 31, 2022 2021 2020 Income taxes paid, net of refunds $ 162,046 $ 108,609 $ 77,163

Pension and other postretirem_2

Pension and other postretirement benefits (Tables)	12 Months Ended
Pension and other postretirement benefits (Tables)	Dec. 31, 2022
Retirement Benefits [Abstract]
Net Benefit Cost of Pension and Postretirement Benefit Plans	The following table provides information regarding the components of the net benefit (income) expense of the pension and postretirement benefit plans for the years ended December 31, 2022, 2021 and 2020: Pension Other Benefits 2022 2021 2020 2022 2021 2020 Service cost $ 1,346 $ 1,467 $ 1,416 $ — $ — $ — Interest cost 10,776 9,272 12,827 477 418 902 Expected return on plan assets (25,776) (30,726) (31,650) — — — Net amortization and deferral 7,900 8,589 7,447 (1,258) (1,058) (161) Net benefit (income) expense $ (5,754) $ (11,398) $ (9,960) $ (781) $ (640) $ 741
Weighted Average Assumptions used in Determining Net Periodic Benefit Cost	The following table provides the weighted average assumptions for U.S. and foreign plans used in determining net benefit cost: Pension Other Benefits 2022 2021 2020 2022 2021 2020 Discount rate 2.8 % 2.5 % 3.2 % 2.7 % 2.3 % 3.1 % Rate of return 5.6 % 6.7 % 7.5 % Initial healthcare trend rate 6.4 % 6.8 % 7.0 % Ultimate healthcare trend rate 4.5 % 4.5 % 5.0 % The following table provides the weighted average assumptions for U.S. and foreign plans used in determining benefit obligations: Pension Other Benefits 2022 2021 2022 2021 Discount rate 5.1 % 2.8 % 5.1 % 2.7 % Rate of compensation increase 3.0 % 2.8 % Initial healthcare trend rate 5.9 % 6.0 % Ultimate healthcare trend rate 4.5 % 4.5 %
Pension and Postretirement Benefit Plans	The following table provides summarized information with respect to the pension and postretirement benefit plans, measured as of December 31, 2022 and 2021: Pension Other Benefits 2022 2021 2022 2021 Benefit obligation, beginning of year $ 474,674 $ 501,347 $ 26,804 $ 31,921 Service cost 1,346 1,467 — — Interest cost 10,776 9,272 477 418 Actuarial (gain) loss (104,558) (13,567) (6,223) (2,288) Currency translation (3,030) (1,726) — — Benefits paid (21,472) (21,138) (2,491) (3,303) Medicare Part D reimbursement — — 53 56 Administrative costs (979) (981) — — Projected benefit obligation, end of year 356,757 474,674 18,620 26,804 Fair value of plan assets, beginning of year 469,793 457,626 Actual return on plan assets (89,506) 22,124 Contributions 1,464 12,159 Benefits paid (21,472) (21,138) Administrative costs (979) (981) Currency translation (2,030) 3 Fair value of plan assets, end of year 357,270 469,793 Funded status, end of year $ 513 $ (4,881) $ (18,620) $ (26,804)
Amounts Recognized in the Consolidated Balance Sheet	The following table sets forth the amounts recognized in the consolidated balance sheet with respect to the pension and postretirement plans: Pension Other Benefits 2022 2021 2022 2021 Other assets $ 16,870 $ 17,827 $ — $ — Payroll and benefit-related liabilities (1,408) (1,602) (2,175) (2,725) Pension and postretirement benefit liabilities (14,949) (21,106) (16,445) (24,079) Accumulated other comprehensive loss (gain) 219,555 218,139 (7,812) (2,847) $ 220,068 $ 213,258 $ (26,432) $ (29,651)
Amounts Recognized in Accumulated Other Comprehensive (Income) Loss	The following tables set forth the amounts recognized in accumulated other comprehensive income with respect to the plans: Pension Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2020 $ 205 $ 232,335 $ (80,657) $ 151,883 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral (5) (8,584) 1,999 (6,590) Amounts arising during the period: Actuarial changes in benefit obligation — (4,965) 1,148 (3,817) Impact of currency translation — (847) 237 (610) Balance at December 31, 2021 200 217,939 (77,273) 140,866 Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral — (7,900) 1,832 (6,068) Amounts arising during the period: Actuarial changes in benefit obligation — 10,724 (2,271) 8,453 Impact of currency translation — (1,408) 365 (1,043) Balance at December 31, 2022 $ 200 $ 219,355 $ (77,347) $ 142,208 Other Benefits Prior Service Cost Net (Gain) or Loss Deferred Taxes Accumulated Other Comprehensive Balance at December 31, 2020 $ (4,669) $ 3,052 $ (9) $ (1,626) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,017 41 (243) 815 Amounts arising during the period: Actuarial changes in benefit obligation — (2,288) 523 (1,765) Balance at December 31, 2021 (3,652) 805 271 (2,576) Reclassification adjustments related to components of Net Periodic Benefit Cost recognized during the period: Net amortization and deferral 1,017 241 (287) 971 Amounts arising during the period: Actuarial changes in benefit obligation — (6,223) 1,419 (4,804) Balance at December 31, 2022 $ (2,635) $ (5,177) $ 1,403 $ (6,409)
Fair Values of Pension Plan Assets	The following table provides the fair values of the pension plan assets at December 31, 2022 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 769 $ 769 — — Money market funds 13 13 — — Equity securities: Managed volatility (b) 46,721 46,721 — — U.S. small/mid-cap equity (c) 6,054 6,054 — — World equity (excluding U.S.) (d) 28,159 28,159 — — Fixed income securities: Intermediate duration fund (e) 105,865 105,865 — — Long duration bond fund (f) 87,018 87,018 — — Corporate bond fund (g) 6,092 6,092 — — Emerging markets debt fund (h) 6,284 6,284 — — Corporate, government and foreign bonds 58,572 — $ 58,572 — Absolute return credit fund (i) 427 — 427 — Asset backed – home loans 153 — 153 — Other types of investments: Structured credit (j) 29 29 — Contract with insurance company (k) 11,114 — — $ 11,114 Total investments at fair value $ 357,270 $ 287,004 $ 59,152 $ 11,114 Total $ 357,270 The following table provides the fair values of the pension plan assets at December 31, 2021 by asset category: Fair Value Measurements Asset Category (a) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash $ 923 $ 923 — — Money market funds 6 6 — — Equity securities: Managed volatility (b) 57,252 57,252 — — U.S. small/mid-cap equity (c) 7,532 7,532 — — World equity (excluding U.S.) (d) 34,287 34,287 — — Fixed income securities: Intermediate duration fund (e) 101,363 101,363 — — Long duration bond fund (f) 171,919 171,919 — — Corporate bond fund (g) 7,607 7,607 — — Emerging markets debt fund (h) 7,605 7,605 — — Corporate, government and foreign bonds 50,599 50,599 — — Absolute return credit fund (i) 671 — $ 671 — Asset backed – home loans 208 — 208 — Other types of investments: Contract with insurance company (k) 19,130 — — $ 19,130 Other 3 — — 3 Total investments at fair value $ 459,105 $ 439,093 $ 879 $ 19,133 Investments measured at Net asset value (l) 10,688 Total $ 469,793 (a) Information on asset categories described in notes (b)-(l) is derived from prospectuses and other material provided by the respective funds comprising the respective asset categories. (b) This category comprises mutual funds that invest in securities of U.S. and non-U.S. companies of all capitalization ranges that exhibit relatively low volatility. (c) This category comprises a mutual fund that invests at least 80% of its net assets in equity securities of small and mid-sized companies. The fund invests in common stocks or exchange traded funds holding common stock of U.S. companies with market capitalizations in the range of companies in the Russell 2500 Index. (d) This category comprises a mutual fund that invests at least 80% of its net assets in equity securities of foreign companies. These securities may include common stocks, preferred stocks, warrants, exchange traded funds based on an international equity index, derivative instruments whose value is based on an international equity index and derivative instruments whose value is based on an underlying equity security or a basket of equity securities. The fund invests in securities of foreign issuers located in developed and emerging market countries. However, the fund will not invest more than 35% of its assets in the common stocks or other equity securities of issuers located in emerging market countries. (e) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including U.S. and foreign corporate obligations, fixed income securities issued by sovereigns or agencies in both developed and emerging foreign markets, debt obligations issued by governments or other municipalities, and securities issued or guaranteed by the U.S. Government and its agencies. The fund will seek to maintain an effective average duration between three (f) This category comprises a mutual fund that invests in instruments or derivatives having economic characteristics similar to fixed income securities. The fund invests in investment grade fixed income instruments, including securities issued or guaranteed by the U.S. Government and its agencies and instrumentalities, corporate bonds, asset-backed securities, exchange traded funds, mortgage-backed securities and collateralized mortgage-backed securities. The fund invests primarily in long duration government and corporate fixed income securities, and uses derivative instruments, including interest rate swap agreements and Treasury futures contracts, for the purpose of managing the overall duration and yield curve exposure of the Fund’s portfolio of fixed income securities. (g) This category comprises funds that invest primarily in higher-yielding fixed income securities, including corporate bonds and debentures, convertible and preferred securities and zero coupon obligations. (h) This category comprises a mutual fund that invests at least 80% of its net assets in fixed income securities of emerging market issuers, primarily in U.S. dollar-denominated debt of foreign governments, government-related and corporate issuers in emerging market countries and entities organized to restructure the debt of those issuers. (i) This category comprises a mutual fund that invests primarily in investment grade bonds and similar fixed income and floating rate securities. (j) This category comprises a fund that invests primarily in collateralized debt obligations and other structured credit vehicles and may include fixed income securities, loan participations, credit-linked notes, medium-term notes, pooled investment vehicles and derivative instruments. (k) This category comprises the asset established out of an agreement to purchase a bulk-annuity policy from an insurer to fully cover the liabilities for members of the pension plan. The asset value is based on the fair value of the contract as determined by the insurance company using inputs that are not observable. (l) This category comprises pooled institutional investments, primarily collective investment trusts. These funds are not listed on an exchange or traded in an active market and these investments are valued using their net asset value, which is generally based on the underlying asset values of the pooled investments held in the trusts. This category comprises the following funds: • a fund that invests primarily in collateralized debt obligations and other structured credit vehicles and may include fixed income securities, loan participations, credit-linked notes, medium-term notes, pooled investment vehicles and derivative instruments. • a hedge fund that invests in various other hedge funds. • funds that invest in underlying funds that acquire, manage, and dispose of real estate properties, with a focus on properties in the U.S. and the UK markets.
Expected Benefit Payments	The following table provides information about the expected benefit payments under its U.S. and foreign plans for each of the five succeeding years and the aggregate of the five years thereafter, net of the annual average Medicare Part D subsidy of approximately $0.1 million: Pension Other Benefits 2023 $ 23,081 $ 2,174 2024 23,445 2,014 2025 23,934 1,986 2026 24,564 1,783 2027 24,940 1,576 Years 2028 — 2032 127,978 6,509

Business segments and other i_2

Business segments and other information (Tables)	12 Months Ended
Business segments and other information (Tables)	Dec. 31, 2022
Segment Reporting [Abstract]
Business segments and other information	The following tables present our segment results for the years ended December 31, 2022, 2021 and 2020: Year Ended December 31, 2022 2021 2020 Americas $ 1,653,724 $ 1,659,309 $ 1,465,035 EMEA 558,373 606,807 584,859 Asia 306,320 297,766 267,016 OEM 272,624 245,681 220,246 Net revenues $ 2,791,041 $ 2,809,563 $ 2,537,156 Year Ended December 31, 2022 2021 2020 Americas $ 452,030 $ 424,225 $ 401,391 EMEA 42,465 94,865 81,348 Asia 82,786 84,648 51,238 OEM 65,379 56,210 44,852 Total segment operating profit (1) 642,660 659,948 578,829 Unallocated expenses (2) (142,935) (31,853) (155,761) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 499,725 $ 628,095 $ 423,068 (1 ) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Commencing on January 1, 2022, all corporate expenses are allocated amongst the segments in proportion to the respective amounts of net revenues. The change in the measure of segment operating profit does not impact period over period comparability because the change was immaterial. For the year ended December 31, 2021, corporate expenses were allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring and impairment charges and gain on sale of business. Year Ended December 31, 2022 2021 2020 Americas $ 162,898 $ 164,102 $ 151,111 EMEA 39,957 45,022 47,012 Asia 10,107 11,140 13,594 OEM 17,628 17,098 15,535 Consolidated depreciation and amortization $ 230,590 $ 237,362 $ 227,252
Total Net Revenues and Total Net Property, Plant and Equipment by Geographic Region	The following tables provide total net revenues and total net property, plant and equipment by geographic region for the years ended December 31, 2022, 2021 and 2020 and as of December 31, 2022 and 2021, respectively. Year Ended December 31, 2022 2021 2020 Net revenues (based on selling location): U.S. $ 1,786,467 $ 1,769,488 $ 1,567,144 Europe 622,343 665,000 646,577 Asia Pacific 270,749 263,022 230,267 All other 111,482 112,053 93,168 $ 2,791,041 $ 2,809,563 $ 2,537,156 As of December 31, Net property, plant and equipment: 2022 2021 U.S. $ 193,618 $ 206,876 Malaysia 73,441 72,541 Mexico 82,334 69,471 All other 97,812 94,870 $ 447,205 $ 443,758

Summary of significant accoun_3

Summary of significant accounting policies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Summary Of Significant Accounting Policies [Line Items]
Allowance for credit losses	$ 8.6	$ 10.8
Current portion of allowance for credit losses	$ 4.9	6
Weighted average amortization period of intangible assets, in years	15 years
Reserve for returns and allowances	$ 17.9	15.2
Reserve for estimated rebates	$ 29	$ 26.4
Sales Revenue, Net \| Hospitals And Healthcare Providers \| Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	88%
Sales Revenue, Net \| Other Medical Device Manufacturers \| Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10%
Sales Revenue, Net \| Home Care Providers such as Pharmacies \| Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	2%
Minimum \| Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	5 years
Minimum \| Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	8 years
Minimum \| Distribution rights
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	10 years
Minimum \| Trade names
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	10 years
Maximum \| Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	20 years
Maximum \| Customer relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	27 years
Maximum \| Trade names
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	30 years
Maximum \| Non-complete agreement
Summary Of Significant Accounting Policies [Line Items]
Useful life of Intangible assets, in years	6 years
Building
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	30 years
Machinery and Equipment \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	3 years
Machinery and Equipment \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	15 years
Computer Equipment and Software \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	3 years
Computer Equipment and Software \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of plant and equipment, in years	10 years

Net revenues - Other revenues (

Net revenues - Other revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Net revenues	$ 2,791,041	$ 2,809,563	$ 2,537,156
Vascular access
Disaggregation of Revenue [Line Items]
Net revenues	683,612	700,240	657,703
Anesthesia
Disaggregation of Revenue [Line Items]
Net revenues	388,890	380,140	302,293
Interventional
Disaggregation of Revenue [Line Items]
Net revenues	445,018	427,500	382,435
Surgical
Disaggregation of Revenue [Line Items]
Net revenues	392,917	377,756	317,200
Interventional urology
Disaggregation of Revenue [Line Items]
Net revenues	322,832	341,661	290,022
OEM
Disaggregation of Revenue [Line Items]
Net revenues	272,624	245,681	220,246
Other
Disaggregation of Revenue [Line Items]
Net revenues	$ 285,148	$ 336,585	$ 367,257

Acquisitions and Divestitures -

Acquisitions and Divestitures - Narrative (Details) $ in Thousands				12 Months Ended			24 Months Ended
	Sep. 27, 2022 USD ($) payment	Jun. 13, 2022 USD ($)	Jun. 28, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2023 USD ($)	May 15, 2021 USD ($)
Business Acquisition [Line Items]
Contingent consideration liability				$ 44,022	$ 9,814
Proceeds from sale of assets				12,434	224,909	$ 1,400
Goodwill				2,536,730	2,504,202	2,585,966
Acquisitions, contingent consideration, liability				43,168	0	0
Late Stage Development Company
Business Acquisition [Line Items]
Payments to acquire productive assets		$ 22,800
Asset acquisition, contingent consideration arrangements, range of outcomes, high		$ 26,200
Useful life of Intangible assets, in years		15 years
Standard Bariatrics
Business Acquisition [Line Items]
Business combination, consideration transferred	$ 211,800
Fair value of consideration transferred	173,000
Contingent consideration liability	38,800
Aggregate contingent consideration amount	$ 130,000
Number of milestone payments \| payment	3
Business combination, contingent consideration, period	3 years
Business combination, acquisition related costs				1,300
Goodwill	$ 71,420
Intangible assets	$ 154,450
Standard Bariatrics \| Maximum
Business Acquisition [Line Items]
Contingent consideration liability				130,000
Respiratory Business \| Disposal Group, Held-for-sale, Not Discontinued Operations
Business Acquisition [Line Items]
Disposal group, including discontinued operation, consideration								$ 286,000
Disposal group, including discontinued operation, working capital								$ 12,000
Proceeds from sale of assets			$ 259,000
Revenue attributable to respiratory business					60,700	$ 138,500
Respiratory Business \| Disposal Group, Held-for-sale, Not Discontinued Operations \| Medline Manufacturing And Supply Transition Agreement
Business Acquisition [Line Items]
Revenue from related parties				$ 79,100	$ 51,100
Respiratory Business \| Disposal Group, Held-for-sale, Not Discontinued Operations \| Forecast
Business Acquisition [Line Items]
Proceeds from sale of assets							$ 15,000

Acquisitions and Divestitures_2

Acquisitions and Divestitures - Summary of Purchase Price Allocation (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 27, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 2,536,730		$ 2,504,202	$ 2,585,966
Standard Bariatrics
Business Acquisition [Line Items]
Current assets		$ 8,028
Property, plant and equipment		3,342
Intangible assets		154,450
Goodwill		71,420
Other assets		2,122
Total assets acquired		239,362
Current liabilities		2,661
Other liabilities		24,896
Liabilities assumed		27,557
Net assets acquired		$ 211,805

Acquisitions and Divestitures_3

Acquisitions and Divestitures - Components of Identifiable Intangible Assets Acquired (Details) - Standard Bariatrics $ in Thousands	Sep. 27, 2022 USD ($)
Intellectual property
Business Acquisition [Line Items]
Intangible assets	$ 128,300
Weighted average useful life (in years)	15 years
Trade names
Business Acquisition [Line Items]
Intangible assets	$ 22,500
Weighted average useful life (in years)	25 years
Customer relationships
Business Acquisition [Line Items]
Intangible assets	$ 3,650
Weighted average useful life (in years)	11 years

Restructuring and impairment _3

Restructuring and impairment charges - Expected costs to be incurred (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Deferred tax assets, valuation allowance	$ 91,531	$ 143,177
2022 restructuring plan
Restructuring Cost and Reserve [Line Items]
Deferred tax assets, valuation allowance	8,100
2022 restructuring plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	39,000
2022 restructuring plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	48,000
Respiratory divestiture plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges		24,000
Respiratory divestiture plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges		30,000
One-time Termination Benefits \| 2022 restructuring plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	18,000
One-time Termination Benefits \| 2022 restructuring plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	22,000
Other costs \| 2022 restructuring plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1,000
Other costs \| 2022 restructuring plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1,000
Restructuring charges \| 2022 restructuring plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	19,000
Restructuring charges \| 2022 restructuring plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	23,000
Restructuring charges \| Respiratory divestiture plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges		5,000
Restructuring charges \| Respiratory divestiture plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges		8,000
Restructuring related charges \| 2022 restructuring plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	20,000
Restructuring related charges \| 2022 restructuring plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 25,000
Restructuring related charges \| Respiratory divestiture plan \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges		19,000
Restructuring related charges \| Respiratory divestiture plan \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges		$ 22,000

Restructuring and impairment _4

Restructuring and impairment charges - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended			19 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Assets impairment charges	$ 1,497	$ 6,739	$ 21,388
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 18,802	14,999	17,103
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of goods sold
Assets impairment charges	$ 1,497	6,739	$ 21,388
2022 restructuring plan
Restructuring Cost and Reserve [Line Items]
Aggregate capital expenditures	2,000
Restructuring expenses	10,100
Restructuring charges	15,523
Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				$ 12,200
Restructuring charges	578	2,694
Respiratory divestiture plan \| One-time Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				3,300
Restructuring charges	8,900	$ 3,300
Minimum \| 2022 restructuring plan
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cash outlays	26,000			26,000
Minimum \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Aggregate capital expenditures	22,000
Maximum \| 2022 restructuring plan
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cash outlays	32,000			$ 32,000
Maximum \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Aggregate capital expenditures	$ 28,000

Restructuring and impairment _5

Restructuring and impairment charges - Reconciliation of changes in accrued liabilities associated with restructuring program (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
2022 restructuring plan
Restructuring Reserve [Roll Forward]
Balance, beginning	$ 0	$ 0
Subsequent accruals	15,523	0
Cash payments	(978)	0
Foreign currency translation and other	315	0
Balance, ending	14,860	0
Respiratory divestiture plan
Restructuring Reserve [Roll Forward]
Balance, beginning	2,601	0
Subsequent accruals	578	2,694
Cash payments	(149)	(7)
Foreign currency translation and other	19	(86)
Balance, ending	3,049	2,601
2019 Footprint realignment plan
Restructuring Reserve [Roll Forward]
Balance, beginning	3,306	8,054
Subsequent accruals	(987)	253
Cash payments	(874)	(4,982)
Foreign currency translation and other	0	(19)
Balance, ending	1,445	3,306
2018 Footprint realignment plan
Restructuring Reserve [Roll Forward]
Balance, beginning	44,065	50,081
Subsequent accruals	2,076	2,476
Cash payments	(24,310)	(4,813)
Foreign currency translation and other	(3,292)	(3,679)
Balance, ending	$ 18,539	$ 44,065

Restructuring and impairment _6

Restructuring and impairment charges - Restructuring program (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 18,802	$ 14,999	$ 17,103
Assets impairment charges	1,497	6,739	21,388
Total restructuring and impairment charges	20,299	21,738	38,491
2022 restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	15,523
Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	578	2,694
2021 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		7,357
2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(987)	253	1,542
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	2,076	2,476	5,948
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	1,612	2,219	766
2020 Workforce reduction plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			8,847
Termination benefits
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	17,385	11,762	14,634
Assets impairment charges	0	0	0
Total restructuring and impairment charges	17,385	11,762	14,634
Termination benefits \| 2022 restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	15,465
Termination benefits \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	504	2,687
Termination benefits \| 2021 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		7,280
Termination benefits \| 2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	(1,120)	(111)	647
Termination benefits \| 2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	1,230	2,335	5,565
Termination benefits \| Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	1,306	(429)	(72)
Termination benefits \| 2020 Workforce reduction plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			8,494
Other costs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	1,417	3,237	2,469
Assets impairment charges	1,497	6,739	21,388
Total restructuring and impairment charges	2,914	9,976	23,857
Other costs \| 2022 restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	58
Other costs \| Respiratory divestiture plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	74	7
Other costs \| 2021 Restructuring plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		77
Other costs \| 2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	133	364	895
Other costs \| 2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	846	141	383
Other costs \| Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 306	$ 2,648	838
Other costs \| 2020 Workforce reduction plan
Restructuring Cost and Reserve [Line Items]
Total restructuring charges			$ 353

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 186,641	$ 146,433
Work-in-process	98,993	81,503
Finished goods	292,873	249,707
Inventory, Net	$ 578,507	$ 477,643

Property, plant, equipment (Det

Property, plant, equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Land, buildings and leasehold improvements	$ 272,578	$ 285,305
Machinery and equipment	462,447	475,040
Computer equipment and software	192,785	191,605
Construction in progress	76,077	49,782
Property, plant and equipment, gross	1,003,887	1,001,732
Less: Accumulated depreciation	(556,682)	(557,974)
Property, plant and equipment, net	$ 447,205	$ 443,758

Goodwill and other intangible_3

Goodwill and other intangible assets - Changes in carrying amount by reporting segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Goodwill			$ 2,918,094
Accumulated impairment losses			(332,128)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,504,202	$ 2,585,966
Goodwill disposed		(35,745)
Goodwill related to acquisitions	71,420	(1,955)
Translation and other adjustments	(38,892)	(44,064)
Goodwill, ending balance	2,536,730	2,504,202
Americas \| Operating Segments
Goodwill [Line Items]
Goodwill			2,032,410
Accumulated impairment losses			(332,128)
Goodwill [Roll Forward]
Goodwill, beginning balance	1,676,224	1,700,282
Goodwill disposed		(21,802)
Goodwill related to acquisitions	53,970	(1,560)
Translation and other adjustments	899	(696)
Goodwill, ending balance	1,731,093	1,676,224
EMEA \| Operating Segments
Goodwill [Line Items]
Goodwill			536,228
Accumulated impairment losses			0
Goodwill [Roll Forward]
Goodwill, beginning balance	492,149	536,228
Goodwill disposed		(7,537)
Goodwill related to acquisitions	7,281	(232)
Translation and other adjustments	(30,906)	(36,310)
Goodwill, ending balance	468,524	492,149
Asia \| Operating Segments
Goodwill [Line Items]
Goodwill			237,446
Accumulated impairment losses			0
Goodwill [Roll Forward]
Goodwill, beginning balance	223,819	237,446
Goodwill disposed		(6,406)
Goodwill related to acquisitions	10,169	(163)
Translation and other adjustments	(8,885)	(7,058)
Goodwill, ending balance	225,103	223,819
OEM \| Operating Segments
Goodwill [Line Items]
Goodwill			112,010
Accumulated impairment losses			$ 0
Goodwill [Roll Forward]
Goodwill, beginning balance	112,010	112,010
Goodwill disposed		0
Goodwill related to acquisitions	0	0
Translation and other adjustments	0	0
Goodwill, ending balance	$ 112,010	$ 112,010

Goodwill and other intangible_4

Goodwill and other intangible assets - Components of intangible assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 3,563,536	$ 3,392,898
Accumulated Amortization	(1,257,371)	(1,103,831)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite lived intangible assets	27,075	28,158
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,328,539	1,328,611
Accumulated Amortization	(497,335)	(441,059)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,599,355	1,440,643
Accumulated Amortization	(646,643)	(560,740)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	23,115	23,434
Accumulated Amortization	(21,090)	(20,630)
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	564,023	549,269
Accumulated Amortization	(71,128)	(59,249)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	21,429	22,783
Accumulated Amortization	$ (21,175)	$ (22,153)

Goodwill and other intangible_5

Goodwill and other intangible assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Intangible asset amortization expense	$ 164,088	$ 165,604	$ 158,685
Trade names
Finite-Lived Intangible Assets [Line Items]
Indefinite lived intangible assets	$ 230,300

Goodwill and other intangible_6

Goodwill and other intangible assets - Estimated annual amortization expense (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 167,100
2024	165,000
2025	164,100
2026	161,300
2027	$ 158,100

Leases - Additional information

Leases - Additional information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Lease, cost	$ 30.8	$ 32.6	$ 30.7
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, option to terminate or extend	1 year

Leases - Maturities of lease li

Leases - Maturities of lease liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2023	$ 24,613
2024	21,483
2025	19,884
2026	19,206
2027	18,338
2028 and thereafter	63,242
Total lease payments	166,766
Less: interest	(26,872)
Present value of lease liabilities	$ 139,894	$ 138,163

Leases - Supplemental balance s

Leases - Supplemental balance sheet information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Lease liabilities	$ 139,894	$ 138,163
Cash paid for amounts included in the measurement of lease liabilities within operating cash flows	28,308	29,199
Right of use assets obtained in exchange for operating lease obligations	$ 25,202	$ 55,290
Weighted average remaining lease term	7 years 10 months 24 days	7 years 10 months 24 days
Weighted average discount rate	4.20%	3.70%

Borrowings - Components of Long

Borrowings - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017
Line of Credit Facility [Line Items]
Long-term debt, Gross	$ 1,723,250	$ 1,863,500
Less: Unamortized debt issuance costs	(11,727)	(13,398)
Net carrying amount	1,711,523	1,850,102
Current portion of borrowings	(87,500)	(110,000)
Long-term borrowings	1,624,023	1,740,102
Revolving Credit Facility
Line of Credit Facility [Line Items]
Long-term line of credit	$ 148,250	$ 141,000
Senior credit facility interest rate	5.80%	1.48%
Securitization Program
Line of Credit Facility [Line Items]
Long-term line of credit	$ 75,000	$ 75,000
Securitization program, at a rate of 5.11% at December 31, 2022 and 1.00% at December 31, 2021	$ 75,000	$ 75,000
Interest rate	5.11%	1%
Term loan facility, at a rate of 5.80% at December 31, 2022 and 1.48% at December 31 2021, due 2027 \| Term Loan
Line of Credit Facility [Line Items]
Long-term line of credit	$ 500,000	$ 647,500
Senior credit facility interest rate	5.80%	1.48%
4.625% Senior Notes due 2027 \| Senior Notes
Line of Credit Facility [Line Items]
Senior notes	$ 500,000	$ 500,000		$ 500,000
Interest rate	4.625%	4.625%		4.625%
4.25% Senior Notes due 2028 \| Senior Notes
Line of Credit Facility [Line Items]
Senior notes	$ 500,000	$ 500,000	$ 500,000
Interest rate	4.25%	4.25%	4.25%

Borrowings - Additional Informa

Borrowings - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Nov. 04, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 454	$ 12,986	$ 0
Securitization Program
Debt Instrument [Line Items]
Interest rate		5.11%	1%
Long-term line of credit		$ 75,000	$ 75,000
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit		$ 148,250	$ 141,000
4.625% Senior Notes due 2027 \| Minimum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount					0.771%
4.625% Senior Notes due 2027 \| Maximum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount					100%
4.625% Senior Notes due 2027 \| Senior Notes
Debt Instrument [Line Items]
Interest rate		4.625%	4.625%		4.625%
Senior notes		$ 500,000	$ 500,000		$ 500,000
Debt issuance, line of credit					$ 7,900
4.625% Senior Notes due 2027 \| Senior Notes \| Maximum
Debt Instrument [Line Items]
Percent of redemption price to principal amount					102.313%
4.25% Senior Notes due 2028 \| Minimum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount				1.0625%
4.25% Senior Notes due 2028 \| Maximum
Debt Instrument [Line Items]
Declining percent of redemption price to principal amount				100%
4.25% Senior Notes due 2028 \| Senior Notes
Debt Instrument [Line Items]
Interest rate		4.25%	4.25%	4.25%
Senior notes		$ 500,000	$ 500,000	$ 500,000
Basis spread on variable rate				0.50%
Debt issuance, line of credit				$ 8,500
Percent of redemption price to principal amount				102.125%
4.25% Senior Notes due 2028 \| Senior Notes \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Percent of redemption price to principal amount on redemption				100%
Makewhole premium as percentage of principal amount of notes subject to redemption				1%
4.25% Senior Notes due 2028 \| Senior Notes \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Percent of redemption price to principal amount on redemption				104.25%
Percent of principal amount of notes redeemable				40%
Third Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Interest rate	2%
Leverage ratio, required		4.50
Interest coverage ratio, required		3.50
Third Amended and Restated Credit Agreement \| Secured Overnight Financing Rate (SOFR) \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.125%
Third Amended and Restated Credit Agreement \| Secured Overnight Financing Rate (SOFR) \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2%
Third Amended and Restated Credit Agreement \| Federal Funds \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
Third Amended and Restated Credit Agreement \| Adjusted SOFR
Debt Instrument [Line Items]
Basis spread on variable rate	1%
Third Amended and Restated Credit Agreement \| Adjusted SOFR \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.125%
Third Amended and Restated Credit Agreement \| Adjusted SOFR \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1%
Third Amended and Restated Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term	5 years
Maximum amount available for borrowing	$ 1,000,000
Third Amended and Restated Credit Agreement \| Term Loan
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 500
Maximum amount available for borrowing	$ 500,000
Debt issuance, line of credit		$ 4,700

Borrowings - Fair Value of Debt

Borrowings - Fair Value of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Level 2
Fair Value Measurements [Line Items]
Fair value of debt	$ 1,674,232	$ 1,893,518

Borrowings - Aggregate Amounts

Borrowings - Aggregate Amounts of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 87,500
2024	12,500
2025	25,000
2026	25,000
2027 and thereafter	$ 1,573,250

Borrowings - Supplemental Cash

Borrowings - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Cash interest paid	$ 70,918	$ 73,598	$ 79,533

Financial instruments - Additio

Financial instruments - Additional Information (Detail)	12 Months Ended
Financial instruments - Additional Information (Detail)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) Financial_Institution_Counterparty	Dec. 31, 2019 EUR (€) Financial_Institution_Counterparty	Dec. 31, 2018 USD ($) Financial_Institution_Counterparty	Dec. 31, 2018 EUR (€) Financial_Institution_Counterparty
Cash Flow Hedging
Derivatives Fair Value [Line Items]
Ineffectiveness on hedging derivatives	$ 0	$ 0	$ 0
Not Designated as Hedging Instrument \| Foreign Currency Exchange Contracts
Derivatives Fair Value [Line Items]
Loss on derivative	3,000,000	8,900,000
Total notional amount for all open foreign currency forward contracts	152,900,000	161,200,000
Designated as Hedging Instrument \| Foreign Currency Exchange Contracts \| Cash Flow Hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	$ 184,800,000	$ 149,500,000
Designated as Hedging Instrument \| Cross Currency Interest Rate Contract
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts				$ 250,000,000	€ 219,200,000	$ 500,000,000	€ 433,900,000
Derivative, number of instruments held \| Financial_Institution_Counterparty				5	5	6	6
Derivative, fixed interest rate				4.875%	4.875%	4.625%	4.625%
Derivative, annual interest rate				2.4595%	2.4595%	1.942%	1.942%

Financial instruments - Schedul

Financial instruments - Schedule of foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange gains	$ (62,904)	$ (63,191)	$ 59,758
Interest benefit on swaps not designed as hedging instrument	20,880	19,296	$ 19,178
Cross Currency Interest Rate Contract \| Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Interest benefit on swaps not designed as hedging instrument	20,880	19,296
Cross Currency Interest Rate Contract \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange gains	$ 22,399	$ 34,849

Financial instruments - Fair va

Financial instruments - Fair value of derivatives (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Prepaid expenses and other current assets
Other assets
Derivatives Fair Value [Line Items]
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other assets
Other liabilities
Derivatives Fair Value [Line Items]
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities
Cash Flow Hedging
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 63,610	$ 33,291
Total liability derivatives	1,460	1,140
Cash Flow Hedging \| Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	51,698	23,731
Cash Flow Hedging \| Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	11,912	9,560
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	1,460	1,140
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Designated as Hedging Instrument \| Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	3,154	1,957
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Designated as Hedging Instrument \| Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	983	993
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Not Designated as Hedging Instrument \| Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	41	56
Cash Flow Hedging \| Foreign Currency Exchange Contracts \| Not Designated as Hedging Instrument \| Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	477	147
Cash Flow Hedging \| Cross Currency Interest Rate Contract \| Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	48,503	21,718
Cash Flow Hedging \| Cross Currency Interest Rate Contract \| Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 11,912	$ 9,560

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 27, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 10,097		$ 19,186
Derivative assets	63,610		33,291
Derivative liabilities	1,460		1,140
Contingent consideration liabilities	44,022		9,814
Standard Bariatrics
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Contingent consideration liabilities		$ 38,800
Standard Bariatrics \| Maximum
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Contingent consideration liabilities	130,000
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	10,097		19,186
Derivative assets	0		0
Derivative liabilities	0		0
Contingent consideration liabilities	0		0
Significant Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0		0
Derivative assets	63,610		33,291
Derivative liabilities	1,460		1,140
Contingent consideration liabilities	0		0
Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0		0
Derivative assets	0		0
Derivative liabilities	0		0
Contingent consideration liabilities	$ 44,022		$ 9,814

Fair value measurement - Valuat

Fair value measurement - Valuation Technique (Details)	Dec. 31, 2022
Revenue-based \| Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.318

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in three financial liabilities measured at fair value on recurring (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Changes in Level 3 Financial Liabilities Related to Contingent Consideration [Roll Forward]
Beginning balance	$ 9,814	$ 36,633
Initial estimate upon acquisition	38,800	0
Payments	(6,975)	(31,678)
Revaluations and other adjustments	2,350	4,895
Translation adjustment	33	(36)
Ending balance	$ 44,022	$ 9,814
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shareholders Equity [Line Items]
Common shares, authorized (in shares)	200,000,000
Common shares, par value (in dollars per share)	$ 1	$ 1
Preference shares, authorized (in shares)	500,000
Preference shares, outstanding (in shares)	0	0	0
Stock Option
Shareholders Equity [Line Items]
Weighted average antidilutive which were not included in the calculation of earnings per share (in shares)	500,000	100,000	100,000

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Basic (in shares)	46,898	46,774	46,488
Dilutive effect of share based awards (in shares)	411	653	799
Diluted (in shares)	47,309	47,427	47,287

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income (loss), net of tax (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 3,754,748	$ 3,336,457
Other comprehensive income (loss) before reclassifications	(58,331)	(56,648)
Amounts reclassified from accumulated other comprehensive income	1,768	6,987
Net current-year other comprehensive income (loss)	(56,563)	(49,661)
Ending Balance	4,021,968	3,754,748
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	1,081	(482)
Other comprehensive income (loss) before reclassifications	7,179	351
Amounts reclassified from accumulated other comprehensive income	(3,329)	1,212
Net current-year other comprehensive income (loss)	3,850	1,563
Ending Balance	4,931	1,081
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(138,290)	(150,257)
Other comprehensive income (loss) before reclassifications	(2,606)	6,192
Amounts reclassified from accumulated other comprehensive income	5,097	5,775
Net current-year other comprehensive income (loss)	2,491	11,967
Ending Balance	(135,799)	(138,290)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(209,750)	(146,559)
Other comprehensive income (loss) before reclassifications	(62,904)	(63,191)
Amounts reclassified from accumulated other comprehensive income	0	0
Net current-year other comprehensive income (loss)	(62,904)	(63,191)
Ending Balance	(272,654)	(209,750)
Accumulated Other Comprehensive Loss (income)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(346,959)	(297,298)
Ending Balance	$ (403,522)	$ (346,959)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income (loss) into income expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 1,259,954	$ 1,259,961	$ 1,212,282
Income from continuing operations before taxes	445,919	559,468	357,732
Taxes on income from continuing operations	(83,003)	(74,349)	(21,931)
Net of tax	362,916	485,119	335,801
Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Impact on income from continuing operations, net of tax	1,768	6,987	7,699
Reclassification out of Accumulated Other Comprehensive Income \| Cash Flow Hedges \| Foreign Exchange Forward
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	(3,532)	1,150	2,354
Income from continuing operations before taxes	(3,532)	1,150	2,354
Taxes on income from continuing operations	203	62	(240)
Net of tax	(3,329)	1,212	2,114
Reclassification out of Accumulated Other Comprehensive Income \| Pension and Other Postretirement Benefit Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income from continuing operations before taxes	6,643	7,531	7,286
Taxes on income from continuing operations	(1,546)	(1,756)	(1,701)
Net of tax	5,097	5,775	5,585
Actuarial losses	7,660	8,543	7,253
Prior-service credits	$ (1,017)	$ (1,012)	$ 33

Stock compensation plans - Addi

Stock compensation plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of common stock authorized to be issued under plan (in shares)	5,300,000
Number of options granted (in shares)	156,918
Unrecognized compensation expense	$ 45
Shares available for future grants (in shares)	2,843,121
Stock option granted, weighted average grant date fair value (in dollars per share)	$ 88.92	$ 103.87	$ 74.60
Stock option granted, weighted average grant date fair value	$ 5	$ 27.4	$ 77.9
Stock option expenses including selling general and administrative expenses	$ 10.3
Non-vested restricted stock units issued (in shares)	85,780	59,210	52,464
Non vested restricted stock expense including selling general and administrative expense	$ 15.7
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options granted (in shares)	156,918
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of restricted stock awards (in shares)	85,780
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense	$ 12.2
Period for recognition	1 year 7 months 24 days
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense	$ 21.2
Period for recognition	1 year 6 months
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of restricted stock awards (in shares)	85,780
Weighted average grant date fair value (in dollars per share)	$ 323.35	$ 398.59	$ 344.70
Performance Shares Units (PSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance period	3 years
Weighted average grant date fair value (in dollars per share)	$ 301
Maximum \| Performance Shares Units (PSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of restricted stock awards (in shares)	62,927
Minimum \| Performance Shares Units (PSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant of restricted stock awards (in shares)	25,131

Stock compensation plans - Shar

Stock compensation plans - Share-based Compensation Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Stock-based compensation	$ 27,224	$ 22,937	$ 20,739
Tax benefit from compensation expense	6,824	10,912	21,958
Net excess tax benefit from compensation expense	$ 1,292	$ 6,355	$ 17,549

Stock compensation plans - Weig

Stock compensation plans - Weighted-average assumptions used to estimate fair value of options granted (Detail) - Stock Options	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Weighted Average Fair Values [Line Items]
Risk-free interest rate	1.56%	0.67%	1.16%
Expected life of option	5 years 10 days	5 years 3 days	5 years
Expected dividend yield	0.41%	0.34%	0.39%
Expected volatility	30.09%	30.03%	23.98%

Stock compensation plans- Summa

Stock compensation plans- Summary of stock option activity (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options, outstanding, beginning of year (in shares) \| shares	1,107,999
Number of options, granted (in shares) \| shares	156,918
Number of options, exercised (in shares) \| shares	(27,518)
Number of options, forfeited or expired (in shares) \| shares	(8,551)
Number of options, outstanding, ending of year (in shares) \| shares	1,228,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price, outstanding, beginning of year (in dollars per share) \| $ / shares	$ 214.13
Weighted average exercise price, granted (in dollars per share) \| $ / shares	330.03
Weighted average exercise price, exercised (in dollars per share) \| $ / shares	95.07
Weighted average exercise price, forfeited or expired (in dollars per share) \| $ / shares	359.54
Weighted average exercise price, outstanding, beginning of year (in dollars per share) \| $ / shares	$ 230.58
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Number of options, exercisable, end of year (in shares) \| shares	990,842
Weighted average exercise price, exercisable, end of year (in dollars per share) \| $ / shares	$ 201.19
Weighted average remaining contractual life in years, outstanding, end of year	4 years 9 months 7 days
Weighted average remaining contractual life in years, exercisable, end of year	3 years 10 months 2 days
Aggregate intrinsic value, outstanding, end of year \| $	$ 66,774
Aggregate intrinsic value, exercisable, end of year \| $	$ 66,746

Stock compensation plans - We_2

Stock compensation plans - Weighted-average assumptions used to estimate fair value of non-vested shares granted (Detail) - Restricted Stock Units	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Weighted Average Fair Values [Line Items]
Risk-free interest rate	1.57%	0.28%	1.07%
Expected dividend yield	0.42%	0.34%	0.38%

Stock compensation plans - Summ

Stock compensation plans - Summary of non vested restricted stock unit activity (Detail) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of non-vested shares, outstanding, beginning of the year (in shares)	135,378
Number of non-vested shares, granted (in shares)	85,780
Number of non-vested shares, vested (in shares)	(51,831)
Number of non-vested shares, forfeited (in shares)	(21,359)
Number of non-vested shares, outstanding, end of the year (in shares)	147,968	135,378
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted average grant date fair value, outstanding, beginning of the year (in dollars per share)	$ 343.89
Weighted average grant date fair value, granted (in dollars per share)	323.35	$ 398.59	$ 344.70
Weighted average grant date fair value, vested (in dollars per share)	290.75
Weighted average grant date fair value, forfeited (in dollars per share)	352.06
Weighted average grant date fair value, outstanding, end of the year (in dollars per share)	$ 349.42	$ 343.89
Weighted average remaining contractual life In years, outstanding, end of the year	1 year 6 months
Aggregate intrinsic value, outstanding, end of the year	$ 36,970

Income taxes - Components of pr

Income taxes - Components of provision for income taxes from continuing operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal	$ 32,798	$ 134,336	$ 11,148
State	8,747	16,970	9,644
Non-U.S.	56,442	35,399	35,042
Deferred:
Federal	(27,528)	(85,272)	(9,475)
State	10,116	(16,933)	(13,734)
Non-U.S.	2,428	(10,151)	(10,694)
Provision for income taxes from continuing operations	$ 83,003	$ 74,349	$ 21,931

Income taxes - Additional Infor

Income taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Contingency [Line Items]
Cumulative unremitted earnings, non-permanently reinvested	$ 1,100,000
Cumulative unremitted earnings, permanently reinvested	$ 1,200,000
Effective income tax rate, total	18.60%	13.30%	6.10%
Realized net benefit as result of reducing our reserves with respect to uncertain tax positions	$ 2,000	$ 800	$ 1,700
Tax effect, carry forwards	110,900
Deferred tax assets, valuation allowance	91,531	143,177
Unrecognized tax benefits that would impact effective tax rate	2,700
Unrecognized tax benefits, interest (benefit) expense	200	200	200
Unrecognized tax benefits, penalties	(200)	(300)	$ (500)
Unrecognized tax benefits, interest (benefit) expense accrued	600	800
Unrecognized tax benefits, penalties accrued	1,500	$ 1,800
Minimum
Income Tax Contingency [Line Items]
Unrecognized tax benefits change within next twelve months due to potential for resolution of foreign and U.S. examinations	0
Maximum
Income Tax Contingency [Line Items]
Unrecognized tax benefits change within next twelve months due to potential for resolution of foreign and U.S. examinations	2,000
No Expiration Date
Income Tax Contingency [Line Items]
Tax effect, carry forwards	16,000
After 2020 but before the end of 2025
Income Tax Contingency [Line Items]
Tax effect, carry forwards	20,100
After 2025
Income Tax Contingency [Line Items]
Tax effect, carry forwards	$ 74,800

Income taxes - Summary of U.S.

Income taxes - Summary of U.S. and non-U.S. components of income from continuing operations before taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S.	$ 164,151	$ 209,231	$ 233,034
Non-U.S.	281,768	350,237	124,698
Income from continuing operations before taxes	$ 445,919	$ 559,468	$ 357,732

Income taxes - Reconciliations

Income taxes - Reconciliations between statutory federal income tax rate and effective income tax rate (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal statutory rate	21%	21%	21%
Tax effect of international items	(4.60%)	(6.00%)	(5.30%)
Legal entity merger - deferred taxes	0%	0%	0%
Excess tax benefits related to share-based compensation	(0.30%)	(1.10%)	(4.90%)
State taxes, net of federal benefit	3.40%	0.10%	(0.30%)
Uncertain tax contingencies	(0.40%)	(0.10%)	(0.50%)
Contingent consideration	0.10%	0.20%	(2.20%)
Intellectual property impairment charge	0%	0%	(1.20%)
Research and development tax credit	(1.00%)	(0.80%)	(1.10%)
Other, net	0.50%	0%	0.60%
Effective income tax rate, total	18.60%	13.30%	6.10%

Income taxes - Deferred tax ass

Income taxes - Deferred tax assets and liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Tax loss and credit carryforwards	$ 110,857	$ 168,113
Lease Liabilities	32,339	32,127
Pension	1,163	350
Reserves and accruals	64,498	64,421
Other	24,013	4,379
Less: valuation allowances	(91,531)	(143,177)
Total deferred tax assets	141,339	126,213
Deferred tax liabilities:
Property, plant and equipment	25,427	24,479
Intangibles — stock acquisitions	379,298	352,139
Unremitted non-U.S. earnings	67,833	73,385
Lease Assets	32,339	32,127
Other	18,926	7,387
Total deferred tax liabilities	523,823	489,517
Net deferred tax liability	$ (382,484)	$ (363,304)

Income taxes - Uncertain tax po

Income taxes - Uncertain tax positions for liabilities associated with unrecognized tax benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 6,105	$ 7,230	$ 7,561
Increase in unrecognized tax benefits related to prior years	215	0	1,286
Decrease in unrecognized tax benefits related to prior years	(761)	0	0
Reductions in unrecognized tax benefits due to lapse of applicable statute of limitations	(1,117)	(956)	(1,864)
(Decrease) increase in unrecognized tax benefits due to foreign currency translation			247
(Decrease) increase in unrecognized tax benefits due to foreign currency translation	(182)	(169)
Ending balance	$ 4,260	$ 6,105	$ 7,230

Income Taxes - Supplemental Cas

Income Taxes - Supplemental Cash Flow (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income taxes paid, net of refunds	$ 162,046	$ 108,609	$ 77,163

Pension and other postretirem_3

Pension and other postretirement benefits - Net benefit cost of pension and postretirement benefit plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 1,346	$ 1,467	$ 1,416
Interest cost	10,776	9,272	12,827
Expected return on plan assets	(25,776)	(30,726)	(31,650)
Net amortization and deferral	7,900	8,589	7,447
Net benefit (income) expense	(5,754)	(11,398)	(9,960)
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	0
Interest cost	477	418	902
Expected return on plan assets	0	0	0
Net amortization and deferral	(1,258)	(1,058)	(161)
Net benefit (income) expense	$ (781)	$ (640)	$ 741

Pension and other postretirem_4

Pension and other postretirement benefits - Weighted average assumptions used in determining net periodic benefit cost (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.80%	2.50%	3.20%
Rate of return	5.60%	6.70%	7.50%
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.70%	2.30%	3.10%
Initial healthcare trend rate	6.40%	6.80%	7%
Ultimate healthcare trend rate	4.50%	4.50%	5%

Pension and other postretirem_5

Pension and other postretirement benefits - Summarized information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation, beginning of year	$ 474,674	$ 501,347
Service cost	1,346	1,467	$ 1,416
Interest cost	10,776	9,272	12,827
Actuarial (gain) loss	(104,558)	(13,567)
Currency translation	(3,030)	(1,726)
Benefits paid	(21,472)	(21,138)
Medicare Part D reimbursement	0	0
Administrative costs	(979)	(981)
Projected benefit obligation, end of year	356,757	474,674	501,347
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning of year	469,793	457,626
Actual return on plan assets	(89,506)	22,124
Contributions	1,464	12,159
Benefits paid	(21,472)	(21,138)
Administrative costs	(979)	(981)
Currency translation	(2,030)	3
Fair value of plan assets, end of year	357,270	469,793	457,626
Funded status, end of year	513	(4,881)
Other Benefits
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation, beginning of year	26,804	31,921
Service cost	0	0	0
Interest cost	477	418	902
Actuarial (gain) loss	(6,223)	(2,288)
Currency translation	0	0
Benefits paid	(2,491)	(3,303)
Medicare Part D reimbursement	53	56
Administrative costs	0	0
Projected benefit obligation, end of year	18,620	26,804	$ 31,921
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Administrative costs	0	0
Funded status, end of year	$ (18,620)	$ (26,804)

Pension and other postretirem_6

Pension and other postretirement benefits - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated benefit obligations for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	$ 345.5	$ 456
Projected benefit obligations for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	346	456.6
Fair value of plan assets for plans with accumulated benefit obligations and projected benefit obligations in excess of plan assets	345.7	449.8
Defined benefit plans, annual average Medicare part D subsidy	0.1
Defined contribution plans, costs	$ 24.3	$ 23.2	$ 21.7
Defined Benefit Plan, Equity Securities
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Target allocation percentage of securities	26%
Fixed Income Securities
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Target allocation percentage of securities	74%
Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.10%	2.80%
Rate of return	5.60%	6.70%	7.50%
Accumulated benefit obligation	$ 356.3	$ 474.1
Expected employer contribution next fiscal year	$ 1.4
Postretirement Health Care Plans
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.10%	2.70%
Expected employer contribution next fiscal year	$ 2.2
Foreign Plan \| Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets with accumulated benefit obligation in excess of plan assets	$ 0.8	$ 2
UNITED STATES \| Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.20%
Rate of return	7.40%	5.80%
UNITED STATES \| Postretirement Health Care Plans
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.13%

Pension and other postretirem_7

Pension and other postretirement benefits - Amounts recognized in consolidated balance sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Payroll and benefit-related liabilities	$ (133,092)	$ (143,657)
Pension and postretirement benefit liabilities	(31,394)	(45,185)
Pension
Defined Benefit Plan Disclosure [Line Items]
Other assets	16,870	17,827
Payroll and benefit-related liabilities	(1,408)	(1,602)
Pension and postretirement benefit liabilities	(14,949)	(21,106)
Accumulated other comprehensive loss (gain)	219,555	218,139
Amounts recognized in balance sheet	220,068	213,258
Other Benefits
Defined Benefit Plan Disclosure [Line Items]
Other assets	0	0
Payroll and benefit-related liabilities	(2,175)	(2,725)
Pension and postretirement benefit liabilities	(16,445)	(24,079)
Accumulated other comprehensive loss (gain)	(7,812)	(2,847)
Amounts recognized in balance sheet	$ (26,432)	$ (29,651)

Pension and other postretirem_8

Pension and other postretirement benefits - Amounts recognized in accumulated other comprehensive (income) loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, accumulated other comprehensive (income) loss, net of tax	$ 346,959
Impact of currency translation, accumulated other comprehensive (income) loss, net of tax	62,904	$ 63,191	$ (59,758)
Ending balance, accumulated other comprehensive (income) loss, net of tax	403,522	346,959
Pension
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, prior service cost (credit)	200	205
Net amortization and deferral, prior service cost	0	(5)
Actuarial changes in benefit obligation, prior service cost	0	0
Impact of currency translation, prior service cost (credit)	0	0
Ending balance, prior service cost (credit)	200	200	205
Beginning balance, net (gain) or loss	217,939	232,335
Net amortization and deferral, net (gain) or loss	(7,900)	(8,584)
Actuarial changes in benefit obligation, net gain (loss)	10,724	(4,965)
Impact of currency translation, net (gain) or loss	(1,408)	(847)
Ending balance, net (gain) or loss	219,355	217,939	232,335
Beginning balance, deferred taxes	(77,273)	(80,657)
Net amortization and deferral, deferred taxes	1,832	1,999
Actuarial changes in benefit obligation, deferred taxes	(2,271)	1,148
Impact of currency translation, deferred taxes	365	237
Ending balance, deferred taxes	(77,347)	(77,273)	(80,657)
Beginning balance, accumulated other comprehensive (income) loss, net of tax	140,866	151,883
Net amortization and deferral, accumulated other comprehensive (income) loss, net of tax	(6,068)	(6,590)
Actuarial changes in benefit obligation, accumulated other comprehensive income (loss), net of tax	8,453	(3,817)
Impact of currency translation, accumulated other comprehensive (income) loss, net of tax	(1,043)	(610)
Ending balance, accumulated other comprehensive (income) loss, net of tax	142,208	140,866	151,883
Other Benefits
Defined Benefit Plan, Chance in Amounts Recognized in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, prior service cost (credit)	(3,652)	(4,669)
Net amortization and deferral, prior service cost	1,017	1,017
Actuarial changes in benefit obligation, prior service cost	0	0
Ending balance, prior service cost (credit)	(2,635)	(3,652)	(4,669)
Beginning balance, net (gain) or loss	805	3,052
Net amortization and deferral, net (gain) or loss	241	41
Actuarial changes in benefit obligation, net gain (loss)	(6,223)	(2,288)
Ending balance, net (gain) or loss	(5,177)	805	3,052
Beginning balance, deferred taxes	271	(9)
Net amortization and deferral, deferred taxes	(287)	(243)
Actuarial changes in benefit obligation, deferred taxes	1,419	523
Ending balance, deferred taxes	1,403	271	(9)
Beginning balance, accumulated other comprehensive (income) loss, net of tax	(2,576)	(1,626)
Net amortization and deferral, accumulated other comprehensive (income) loss, net of tax	971	815
Actuarial changes in benefit obligation, accumulated other comprehensive income (loss), net of tax	(4,804)	(1,765)
Ending balance, accumulated other comprehensive (income) loss, net of tax	$ (6,409)	$ (2,576)	$ (1,626)

Pension and other postretirem_9

Pension and other postretirement benefits - Weighted average assumptions used in determining benefit obligations (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Pension
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.10%	2.80%
Rate of compensation increase	3%	2.80%
Other Benefits
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.10%	2.70%
Initial healthcare trend rate	5.90%	6%
Ultimate healthcare trend rate	4.50%	4.50%

Pension and other postretire_10

Pension and other postretirement benefits - Fair values of pension plan assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Maximum percentage of net assets invested in emerging market	35%
Minimum
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Effective average duration to maintain	3 years
Maximum
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Effective average duration to maintain	10 years
Emerging markets debt fund
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Percentage of net assets invested in foreign equity securities	80%
Small and Mid-Sized Companies \| Equity Securities \| U.S. Russell 2500 Index
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Percentage of net assets invested	80%
Foreign Companies
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Percentage of net assets invested in foreign equity securities	80%
Fair Value, Measurements, Recurring
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	$ 357,270	$ 469,793
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	357,270	459,105
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	287,004	439,093
Fair Value, Measurements, Recurring \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	59,152	879
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	11,114	19,133
Fair Value, Measurements, Recurring \| Fair Value Measured at Net Asset Value Per Share
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		10,688
Fair Value, Measurements, Recurring \| Cash \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	769	923
Fair Value, Measurements, Recurring \| Cash \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	769	923
Fair Value, Measurements, Recurring \| Cash \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Cash \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Money market funds \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	13	6
Fair Value, Measurements, Recurring \| Money market funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	13	6
Fair Value, Measurements, Recurring \| Money market funds \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Money market funds \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Managed Volatility \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	46,721	57,252
Fair Value, Measurements, Recurring \| Managed Volatility \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	46,721	57,252
Fair Value, Measurements, Recurring \| Managed Volatility \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Managed Volatility \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| U.S. Small/Mid-Cap Equity \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	6,054	7,532
Fair Value, Measurements, Recurring \| U.S. Small/Mid-Cap Equity \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	6,054	7,532
Fair Value, Measurements, Recurring \| U.S. Small/Mid-Cap Equity \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| U.S. Small/Mid-Cap Equity \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| World equity (excluding U.S.) \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	28,159	34,287
Fair Value, Measurements, Recurring \| World equity (excluding U.S.) \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	28,159	34,287
Fair Value, Measurements, Recurring \| World equity (excluding U.S.) \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| World equity (excluding U.S.) \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Intermediate duration bond fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	105,865	101,363
Fair Value, Measurements, Recurring \| Intermediate duration bond fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	105,865	101,363
Fair Value, Measurements, Recurring \| Intermediate duration bond fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Intermediate duration bond fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Long duration bond fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	87,018	171,919
Fair Value, Measurements, Recurring \| Long duration bond fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	87,018	171,919
Fair Value, Measurements, Recurring \| Long duration bond fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Long duration bond fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Corporate bond fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	6,092	7,607
Fair Value, Measurements, Recurring \| Corporate bond fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	6,092	7,607
Fair Value, Measurements, Recurring \| Corporate bond fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Corporate bond fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Emerging markets debt fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	6,284	7,605
Fair Value, Measurements, Recurring \| Emerging markets debt fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	6,284	7,605
Fair Value, Measurements, Recurring \| Emerging markets debt fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Emerging markets debt fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Corporate, government and foreign bonds \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	58,572	50,599
Fair Value, Measurements, Recurring \| Corporate, government and foreign bonds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	50,599
Fair Value, Measurements, Recurring \| Corporate, government and foreign bonds \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	58,572	0
Fair Value, Measurements, Recurring \| Corporate, government and foreign bonds \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Absolute return credit fund \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	427	671
Fair Value, Measurements, Recurring \| Absolute return credit fund \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Absolute return credit fund \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	427	671
Fair Value, Measurements, Recurring \| Absolute return credit fund \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Asset backed – home loans \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	153	208
Fair Value, Measurements, Recurring \| Asset backed – home loans \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Asset backed – home loans \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	153	208
Fair Value, Measurements, Recurring \| Asset backed – home loans \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Structured Credit \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	29
Fair Value, Measurements, Recurring \| Structured Credit \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	29
Fair Value, Measurements, Recurring \| Structured Credit \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets
Fair Value, Measurements, Recurring \| Structured Credit \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0
Fair Value, Measurements, Recurring \| Contract with insurance company \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	11,114	19,130
Fair Value, Measurements, Recurring \| Contract with insurance company \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Contract with insurance company \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	0	0
Fair Value, Measurements, Recurring \| Contract with insurance company \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets	$ 11,114	19,130
Fair Value, Measurements, Recurring \| Other \| Fair Value, Inputs, Level 1, 2 and 3
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		3
Fair Value, Measurements, Recurring \| Other \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring \| Other \| Significant Observable Inputs (Level 2)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		0
Fair Value, Measurements, Recurring \| Other \| Significant Unobservable Inputs (Level 3)
Schedule Of Pension Plan Assets By Fair Value [Line Items]
Fair value of plan assets		$ 3

Pension and other postretire_11

Pension and other postretirement benefits - Expected benefit payments (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Pension
Schedule Of Pension Expected Future Benefit Payments [Line Items]
2023	$ 23,081
2024	23,445
2025	23,934
2026	24,564
2027	24,940
Years 2028 — 2032	127,978
Other Benefits
Schedule Of Pension Expected Future Benefit Payments [Line Items]
2023	2,174
2024	2,014
2025	1,986
2026	1,783
2027	1,576
Years 2028 — 2032	$ 6,509

Commitments and contingent li_2

Commitments and contingent liabilities - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Italian parliament legislation
Loss Contingencies [Line Items]
Loss contingency, estimate of possible loss	$ 23
Loss contingency accrual	10.9
Loss contingency, loss in period	$ 2.6
Minimum
Loss Contingencies [Line Items]
Estimated time frame over which accrued amounts may be paid out	10 years
Minimum \| China investigation, unpaid tariffs
Loss Contingencies [Line Items]
Loss contingency accrual, unpaid tariff, penalties percentage	30%
Loss contingency, estimate of possible loss	$ 3
Maximum
Loss Contingencies [Line Items]
Estimated time frame over which accrued amounts may be paid out	15 years
Maximum \| China investigation, unpaid tariffs
Loss Contingencies [Line Items]
Loss contingency accrual, unpaid tariff, penalties percentage	200%
Loss contingency, estimate of possible loss	$ 20
Accrued Liabilities
Loss Contingencies [Line Items]
Waste disposed accrued liability	$ 2.5	$ 2
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Contingency reserve for litigation	$ 0.5	$ 0.2
Other Liabilities
Loss Contingencies [Line Items]
Waste disposed accrued liability	$ 3.2	$ 4.1
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities

Business segments and other i_3

Business segments and other information - Segment Result (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Revenues From External Customers And Long Lived Assets [Line Items]
Number of reportable segments \| segment	4
Net revenues	$ 2,791,041	$ 2,809,563	$ 2,537,156
Operating profit	499,725	628,095	423,068
Depreciation and amortization	230,590	237,362	227,252
Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Operating profit	642,660	659,948	578,829
Segment Reconciling Items
Revenues From External Customers And Long Lived Assets [Line Items]
Operating profit	(142,935)	(31,853)	(155,761)
Americas
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	162,898	164,102	151,111
Americas \| Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	1,653,724	1,659,309	1,465,035
Operating profit	452,030	424,225	401,391
EMEA
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	39,957	45,022	47,012
EMEA \| Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	558,373	606,807	584,859
Operating profit	42,465	94,865	81,348
Asia
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	10,107	11,140	13,594
Asia \| Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	306,320	297,766	267,016
Operating profit	82,786	84,648	51,238
OEM
Revenues From External Customers And Long Lived Assets [Line Items]
Depreciation and amortization	17,628	17,098	15,535
OEM \| Operating Segments
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	272,624	245,681	220,246
Operating profit	$ 65,379	$ 56,210	$ 44,852

Business segments and other i_4

Business segments and other information - Total net revenues and total net property, plant and equipment by geographic region (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net revenues	$ 2,791,041	$ 2,809,563	$ 2,537,156
Property, plant and equipment, net	447,205	443,758
UNITED STATES
Segment Reporting Information [Line Items]
Net revenues	1,786,467	1,769,488	1,567,144
Property, plant and equipment, net	193,618	206,876
Europe
Segment Reporting Information [Line Items]
Net revenues	622,343	665,000	646,577
Asia Pacific
Segment Reporting Information [Line Items]
Net revenues	270,749	263,022	230,267
All other
Segment Reporting Information [Line Items]
Net revenues	111,482	112,053	$ 93,168
Property, plant and equipment, net	97,812	94,870
Malaysia
Segment Reporting Information [Line Items]
Property, plant and equipment, net	73,441	72,541
Mexico
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 82,334	$ 69,471

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 10,800
Balance at End of Year	8,600	$ 10,800
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	10,799	12,875	$ 9,055
(Reversals) additions Charged to Income	(786)	1,542	3,798
Accounts Receivable Write-offs	(1,750)	(3,001)	(1,336)
Translation and Other	299	(617)	1,358
Balance at End of Year	$ 8,562	$ 10,799	$ 12,875

SCHEDULE II - VALUATION AND Q_3

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS - DEFERRED TAX ASSET VALUATION ALLOWANCE (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 143,177
Balance at End of Year	91,531	$ 143,177
Valuation Allowance of Deferred Tax Assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	143,177	155,008	$ 119,233
(Reversals) additions Charged to Income	8,489	7,770	30,640
Accounts Receivable Write-offs	(59,520)	(15,384)	(59)
Translation and Other	(615)	(4,217)	5,194
Balance at End of Year	$ 91,531	$ 143,177	$ 155,008